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INTRODUCTION 
The 29th Annual Stoneburner Lecture Series 
was sponsored this year by the Department of 
Neurology because we sensed a need and a desire for 
a symposium approaching common neurologic prob-
lems encountered by primary care physicians. The 
attendance at the series was gratifying to the partici -
pating lecturers and confirmed our view . 
Our approach to each topic has been to dwell on 
recognition and diagnosis, and to discuss new therapy 
and therapeutic dilemmas, omitting or touching only 
briefly on such areas as basic anatomy, physiology, 
chemistry, and pathology. In this first part of a two-
part issue, I discuss some of the problems of treating 
Parkinson ' s disease that somehow have not been 
solved by the highly touted levodopa, Dr. Harbison 
provides us with an overview of sometimes vexing 
problems that present as episodic visual loss, and Dr. 
Grindal provides us with a rational approach to dizzy 
patients. Our Stoneburner Lecturer, Dr. Clark Milli-
kan, offers an in-depth review of cerebrovascular 
insufficiency. Finally, Dr. Calabrese covers the value 
of the cerebrospinal fluid examination and certain 
measures that may be taken to improve interpreta-
tion. 
In organizing this symposium, we have at-
tempted to provide the primary care physician with 
some insight, perhaps new, into these complex and 
common areas, but it is necessary for primary care 
physicians themselves to continue providing us with 
information about their problem areas . 
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James Parkinson, a London general practitioner 
and political activist, 1 delivered his essay on the shak-
ing palsy in 1817 and encouraged others who "hu-
manely employ anatomical examination " to study 
the cause and nature of "this malady." Even in his 
wildest fantasies I seriously doubt that he dreamed of 
the extent to which his advice would be followed . 
Today, in spite of a recog.nized incidence of only 20 
cases per 100,000 persons per year,2 articles con-
cerning this disorder appear in nearly every issue of 
many neurology journals. The reason for this interest 
is explained by the significant work that took place in 
the 1960's. During that period a series of biochemical 
steps leading from tyrosine to biogenically active 
amines was elucidated,3 and, further, the action of 
these amines at brain synapses was convincingly hy-
pothesized.4 Tyrosine is converted to levodopa and 
then to dopamine, a neurotransmitter. Since dopa-
mine parenterally does not enter the brain , it was 
found that large doses of its precursor, levodopa, 
resulted in some levodopa entering the brain, driving 
the reaction in favor of more dopamine, and there-
fore enhancing neurotransmission. It is this concept 
that has excited neurologists out of all proportion to 
the frequency of Parkinson's disease in the genera l 
population. As is now known , the pathology of Park-
inson's disease lies in the substantia nigra, 5 where 
neurons that ordinarily project to the striatum 6 and 
transmit via dopamine are degenerating; hence the 
rationale for the use of levodopa as a therapeutic 
tool. As attractive as this model is, I remain sus-
picious that the mechanisms are far more complex 
than as yet determined. 
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In the management of Parkinson's disease, one 
must be reasonably certain of the diagnosis. In spite 
of the foregoing sophisticated biochemistry , there is 
really no laboratory test for the disease, so it becomes 
an entity that must be recognized on purely clinical 
grounds. While the differential diagnosis can be quite 
extensive and includes such rare entities as manga-
nese poisoning, as well as such usually apparent 
causes as phenothiazine intoxication or carbon mon-
oxide sequelae, several disorders and etio logies ac-
count for most of our diagnostic problems. Although 
we think of Parkinsonism as a triad of rest tremor, 
rigidity , and akinesia, the onset may be with any one 
of these, and if it is with tremor, the distinction from 
essential tremor may be difficult. Essential tremor, 
sometimes inherited as an autosomal dominant, is 
occasiona ll y seen and resembles Parkinson's disease. 
The tremor is a little faster7 and while many authors 
state that it begins in an arm, as does Parkinsonism, 
the head often begins to titubate soon after the 
tremor begins in the hand. The onset of essential (or 
familial) tremor is usually earlier than in Parkinson ' s 
disease, and may even be in childhood. Its progres-
sion is slow, and it often stabi li zes so that the physi-
cian may encounter a patient who recounts years of 
tremor, often misdiagnosed as nervousness or Park-
insonism . The rigidity and akinesia of the latter are 
never present in essential tremor. Patients with essen-
tial tremor usually display more tremor on intention 
than at rest, and often find that a moderate amount 
of alcohol relieves their tremor for a time. The combi-
nation of family history , long-standing symptoms, 
head titubation, and absence of either rigidity or 
akinesia will almost a lways estab li sh the diagnosis of 
essential tremor. Levodopa is of no value . 
Cerebell ar tremor associated with cerebellar 
degeneration or other cerebellar diseases is an occa-
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sional problem. Usually the absence of rest tremor, 
akinesia, and rigidity, plus other signs, for example, 
truncal ataxia, will allow an easy distinction. 
A variety of degenerative diseases may present 
with poverty of motion and a degree of rigidity. Most 
of the presenile dementias can present in this fashion, 
but the predominance of the dementing element usu-
ally permits an easy differential diagnosis to be made. 
Certain rare entities have been a problem, however, 
one of which is progressive supranuclear palsy.8 
Patients with this disease display many Parkinsonian 
features, including, occasionally , involuntary move-
ments; however, early loss of voluntary vertical gaze, 
especially down gaze (with spared reflex gaze mecha-
nisms, for example, oculovestibular reflexes) asso-
ciated with conspicuous rigidity , along with a fairly 
rapid course, are usually enough to permit most clini-
cians to arrive at the diagnosis. Levodopa is of lim-
ited, if any, benefit. 
Shy-Drager syndrome (idiopathic orthostatic 
hypotension )9 is another rare syndrome that has led 
to some diagnostic difficulty, though usually easily 
resolved . This disease reflects, to some extent, a con-
tinuum of Parkinsonism; however, the Shy-Drager 
syndrome evinces a much more profound in-
volvement of autonomic nuclei , with consequent se-
vere orthostatic hypotension, anhidrosis, and in-
continence, to the degree that the usually present 
bradykinesia , rigidity, and occasional tremor are 
overshadowed. Nevertheless, since orthostatic hypo-
tension is occasionally a feature of Parkinsonism, the 
distinction is sometimes a problem. Patients with 
Shy-Drager syndrome respond poorly to levodopa . 
A part from these syndromes, the differential 
diagnosis of Parkinson's disease revolves mainly 
around its etiology. Though some reputable in-
vestigators appear to feel that the encephalitis epi-
demic in the second and third decades of this century 
accounts for most of the Parkinsonism we see, I 
believe that there are multiple etiologies for the dis-
ease just as there are for hemiplegia , and that the duty 
of physicians encountering patients with Park-
insonism is to attempt to elucidate the etiology. 
Another area of interest that should be men-
tioned is genetic Parkinson's disease. 10 There is abun-
dant evidence that familial clustering occurs in 
Parkinsonism, and the finding that individuals 
predisposed to developing Parkinsonian symptoms, 
after treatment with phenothiazines, have a higher 
incidence of family members with spontaneous Park-
inson's disease" adds further weight to the idea that 
some Parkinsonism is hereditary , perhaps an inher-
ited tyrosine hydroxylase deficiency. Nevertheless, 
this is not sufficiently established to require ge-
netic counseling, nor is hereditary Parkinsonism suf-
ficiently different from other forms to necessitate dif-
ferences in therapy. Furthermore, familial clustering 
alone is insufficient evidence to rule out an infectious 
etiology . 
Therapeutic avenues open to the physician man-
aging patients with Parkinson's disease can best be 
summarized by considering the past, present, and 
future. That the treatment of this complex disease 
should change over the years is not surprising; how-
ever, that the treatment should take such profound 
swings over a period of fifteen years is surprising. 
The Past. Charcot is said to have noted the value 
of atropine over 100 years ago. 12 Since then , and until 
levodopa appeared on the scene, atropine and about 
seven or eight similar drugs were the medications of 
choice in Parkinson's disease . The differences in these 
drugs are not great, 13 and all share, to a variable 
degree, anticholinergic side effects . The peripheral 
side effects of these drugs are well known; however, 
centrally, drug intoxication may lead to ataxia, dys-
arthria, hyperthermia, and frank psychosis. The 
drugs must be introduced in low dosages and in -
creased slowly until improvement occurs or side ef-
fects force a halt to further increment of dosage. A 
modest improvement in rigidity and tremor can be 
expected in 70% of patients; however, akinesia does 
not respond to this treatment.14 These drugs remain 
valuable in the treatment of mild Parkinsonism and 
as adjuncts to levodopa. Diphenhydramine (Ben-
adryl@), an antihistamine, also possesses an atro-
pine-like action, inhibiting striatal dopamine uptake, 
and is only mildly less potent than benztropine (Co-
gentin@). 
Amphetamines enjoyed some popularity in the 
past. These drugs are chemically similar to dopamine 
and seem to be beneficial. Their benefits , however, 
are not great enough to override their side effects, and 
they are no longer used to any extent. Surgery, in-
volving destructive lesions in several areas of the 
brain, but mostly in the thalamus, enjoyed a brief 
popularity in the fifties and early sixties . Useful 
mainly for tremor and least valuable in akinesia, 
thalamotomy procedures were often impermanent in 
their benefits and had occasional failures as well as 
complications, such as hemiplegia. As a result, the 
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use of thalamotomy waned rapidly after the devel-
opment of levodopa, and the operation is now rarely 
performed for Parkinson's disease. 
The Present. Long in preparation, levodopa has 
been in widespread experimental use for over seven 
years, and in general use for over five years. 15 First 
evaluations, particularly with patients early in the 
course of their disease, indicated that 70% of patients 
experienced at least a 50% improvement in their 
symptoms, especially akinesia and rigidity. This is a 
remarkable improvement for most patients. To 
achieve this goal, the d?ily dosage must be slowly 
worked up to levels of 5 to 9 gm, initiated at levels of 
125 to 250 mg daily, with food. Single doses should 
not exceed 1.5 to 2.0 gm 13; hence the need for multiple 
doses. The frequency of side effects is extensive. In 
one series of 100 patients,16 49 developed abnormal 
involuntary movements, 45 had gastrointestinal 
problems, 30 had psychiatric manifestations, and 11 
had symptomatic hypotension . Other side effects oc-
curred less frequently. As a result of these side effects, 
especially nausea, many patients never reach max-
imum dose levels, and treatment is discontinued be-
cause they cannot tolerate useful levels of the drug. 
Part of this problem has been solved by combining 
levodopa with carbidopa which is a chemical "look-
alike" of levodopa that inhibits dopa-decarboxylase 
extracerebrally. Thus, since 95% of levodopa is de-
carboxylated before it reaches the brain 17 (and is 
therefore therapeutically ineffective), a combinat~on 
drug allows levodopa to reach the brain in greater 
amounts respective to the oral dose. The only combi-
nation currently available commercially is Sinemet 
25/ 250® (Merck, Sharp, and Dohme). This product 
provides a carbidopa: levodopa ratio of I : I 0, and 
since carbidopa blocks at least 75% to 80% of periph-
eral decarboxylation of levodopa, it follows that a 
Sinemet 25/250® is roughly equivalent to 1.0 gm of 
oral levodopa, and in practice this seems to be the 
case. In switching from levodopa to Sinemet 25/250®, 
stop levodopa for 8 hours, then resume Sinemet 25/ 
250® at one-fourth the dose for levodopa. The only 
real advantage to the com bi nation is the avoidance of 
nausea, though a reduction in cardiac arrhythmias 
and in hypotension has been reported .17 According to 
an oral communication from B. A. Huffman, in Feb-
ruary 1976, the price of this combination drug is 
15% to 20% above levodopa a lone and since its chief 
value is in preventing nausea, the increased expense is 
hardly justified for those who tolerate, one way or the 
other, this side effect. Nonetheless, this combination 
drug offers a considerable advantage to those patients 
who seem unable to overcome nausea at even low 
doses. In addition, and of minor importance with 
out-patients, one can advance the dosage faster with 
combination therapy since nausea is a minimal prob-
lem. Finally, carbidopa inhibits the action of pyri-
doxine in reversing levodopa action; hence ordinary 
multivitamins may be used when indicated. 
Other side effects that deserve special mention 
are the involuntary movements and the psychologic 
problems. Both can take almost any form, both are 
quite common complications, and, as a rule, the de-
velopment of either problem is best managed by a 
reduction in dose. Both are central effects of levo-
dopa; hence they readily occur with either levodopa 
alone or in combination with carbidopa. 
A final note on side effects relates to orthostatic 
hypotension. This is a well-recognized side effect, and 
patients on levodopa should have periodic standing 
blood pressure determinations. A reduction in levo-
dopa dose is usually required if this side effect occurs. 
Other drugs may also be used to advantage with 
levodopa or levodopa/carbidopa. Atropine-like 
agents have already been mentioned, and while they 
were never shown to provide more than a 20% im-
provement in symptoms, this margin may occasion-
ally be useful along with levodopa. Amantadine, 
originally an antiviral drug, has more merit as an 
adjunct as well as acting alone. In one study18 in-
volving 48 patients, benefits of 21 % to 39% occurred 
in major Parkinsonian disabilities. Side effects, con-
sisting mainly of gastrointestinal disturbances, sleep 
disturbances, and hallucinations occurred with 
amantadine, but the frequency of these is low. The 
dose used in this study was amantadine 200 mg daily 
in divided doses. There is a tendency for benefits to 
decline after several months. 
Propranolol, a beta adrenergic blocking agent, 
has also been used in a va riety of states with 
tremor 19•20 and consequently we have tried it in com-
bination with other drugs to relieve the tremor of 
Parkinson's disease. The results have not been mea-
sured, but on occasion this has seemed to be a useful 
drug. Other clinicians21 have had similar experiences. 
A maximum dose of 180 to 200 mg/ day must be 
approached cautiously. 
One may wonder why several drugs other than 
levodopa have been mentioned. Several facets of the 
nature of levodopa therapy account for this. First, a 
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fairly large group of patients do not respond well to 
it. Second, certain patients are unable to achieve ade-
qua te levels due to side effects. And, finally, there 
appears to be developing a "resistance" to levodopa 
benefit.15 This resistance takes several forms, but oc-
curs in one way or another in the majority of pati ents. 
In Barbeau's series, the percentage of patients with 
excellent or good results initially was 79% and 
dropped to 29% at 6 years, and 25% had stopped 
levodopa. The predicted survival of severely akinetic 
patients is 9.7 years,22 thus it is suggested that 
levodopa probably will not stop the progression of 
Parkinsonism. Some investigators feel that there may 
be a finite period of time in which levodopa is effec-
tive and therefore withold the drug until disability is 
beginning to become clearly evident. 
The resistance to treatment ta kes many forms, 
but three mechanisms stand out: 
I. End-of-dose ak inesia. Parkinsonian symp-
toms recur progressively earlier following a dose. 
Levodopa levels are low, and more frequent spacing 
of the drug is beneficial. 
2. On / Off phenomenon . Patients note periods 
in which there is a sudden return of Parkinsonian 
symptom s, the " Off' ' period. The " On" period, un-
fortunately, is nearly always complicated by dyski-
nesias , usually appendicular and fairly distressing. In 
one report,23 29 such patients were encountered in a 
population of 300 Parkinson patients. Nineteen had 
been on medication more than 24 months, suggesting 
that the duration of the di sease or of levodopa ther-
apy is of significance. The "Off'' period is character-
ized by low levodopa levels. This phenomenon is 
poorly understood a nd its management a subject of 
debate. Nevertheless, two views are worth men-
tioning. The first24 embraces the concept that a hyper-
sensitivity of the receptor occurs and suggests gradual 
reduction in levodopa dose to levels of about one-
fifth the previous maintena nce dose. The second25 
involves a reduction in presumably competing amino 
acids in the diet by reducing protein intake from the 
normal 1.0 to 2.0 gm/ kg to .5 gm/ kg, along with the 
usual dosages of levodopa and an inhibitor. Both 
methods, as well as a variety of other drug manipu-
lations, have some merit; however, this problem re-
ma ins quite serious. 
3. Akinesia paradoxica. Sudden "blocking" 
seems to occur, often triggered by a sudden change in 
afferent sensory input (as unexpected stress), and the 
patient "freezes," often falling. Blood levels of levo-
do pa are usually high ,21 and the theory is that there is 
a sudden, unanswered demand on the noradrenalin 
" drive" mecha ni sm, now depleted by involvement of 
the locus ceruleus.21 Fortunately, this complication is 
quite uncommon, since its management and patho-
genesis rema in uncerta in. 
In numerous other ways, and in spite of many 
drugs, Parkinsonian patients seem to gradually lose 
the benefit of medication and deteriorate after a num-
ber of years. 
Several other facets of the treatment of Park-
insonism deserve special mention. A certain number 
of patients develop a mild-to-moderate dementi a. 26 
This part of the picture does not seem to be wholly 
reversible with levodopa and thus becomes part of 
the overall management. Discussion of this is beyond 
the scope of this paper. Another important part of 
present management is physical therapy. The motiva-
tion and assistance provided by this moda lity is of 
inestimable value, and no experienced clinician 
doubts the value of maintaining mobility in the 
patient with Parkinsonism . Seriously a ffected pa-
tients are best cared for by facilities offering this form 
of treatment. 
Evaluation of the physician 's treatment is quite 
important, since the probability of eventual failure is 
high . With a ny given patient , the physicia n must 
establish methods of continuing patient evaluation 
that include such actions as rising from a chair, hand-
writing, drawing whorls, and activities of daily liv-
ing.17 Once clear regression occurs, efforts at com-
bating this, while often futile, must be instituted , and 
a periodic semi-quantitative evaluation of the patient 
is useful. 
The Future. A number of pharmacologic at-
tempts to alter Parkinson's disease are in progress, 
but most show little potential. Two that show the 
greatest possibility of success presently are bromo-
criptine21·28 a nd apomorphine. 
Bromocriptine, a n ergot alkaloid containing a 
lysergic-acid residue, activates dopam inergic recep-
. tors. The evidence cited is but a single study in which 
19 patients received an optimum dose of 20 to 75 mg 
daily; the original study consisted of 28 patients, but 
I failed to follow directions and 8 had intolerable side 
effects. Side effects, usually dose dependent, were in 
every way similar to levodopa, except for four new 
reactions: erythema, edema, and tenderness of the 
a nkles; burning discomfort of the eyes; diplopia; and 
frequent extrasystoles. Of the 19 who continued 
bromocriptine, all but 4 were able to omit their levo-
dopa or levodo pa/ carbidopa. All noted improvement 
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of Parkinsonian symptoms while on bromocriptine as 
compared to a placebo, but the authors were unable 
to draw any conclusion comparing bromocriptine 
and levodopa. The drug appears to have some 
promise, particularly since it obviates the necessity of 
having endogenous dopa decarboxylase, which is also 
depleted in the striatum of Parkinsonian patients as 
the disease progresses. 
A second drug offering some promise is N-pro-
pylnoraporphine, an analog of apomorphine having 
a nephrotoxic dose far in excess of its therapeutic 
dose.29 In the series by Cotzias et al,29 all 24 patients 
improved, and the "On-Off" phenomenon of 6 
patients, still present on N-propylnoraporphine 
alone, was abolished by co-administration of alpha-
methyl dopahydrazine. Side effects, including drug-
related rena l toxicity in two patients, were not un-
common, a nd further evaluation is necessa ry. 
Summary. While an exhaustive review of avai l-
able management has not been attempted, the fre-
quently missed differential diagnoses and important 
therapeutic modalities have been discussed . No treat-
ment seems to stay the inexorable progression of this 
disease, but several avenues offer the patient a better 
quality of life as the disease proceeds. 
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Episodic Disorders of Vision 
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Introduction. 
Of all our senses, vision is most commonly asso-
ciated with patient distress, if not overt alarm, when 
abruptly compromised. 
Despite patient concern, a rare, or rarely recog-
nizable, clinical entity is perhaps of less significance 
to the physician than to the patient. When the broad 
spectrum of episodic disturbance of vision is closely 
examined, it becomes apparent that these visual 
symptoms are indeed of common occurrence in the 
population at large. 
Surprisingly, despite their ultimate effect on the 
eye, a majority of the clinical entities that produce 
episodic disturbance of vision are neurologic (Fig 1 ). 
Episodic is defined as being " ... made up of 
separate, loosely connected episodes."* In turn, an 
episode is " .. . a usually brief unit of action ... an 
occurrence or connected series of occurrences and 
developments which may be viewed as distinctive and 
apart, although part of a larger or more comprehen-
sive series ."* 
In binocular man, episodic visual change has 
two essential parameters of basic diagnostic signifi-
cance: Time and laterality. 
In terms of time, an episode has both duration 
and frequency. Although both characteristics are of 
diagnostic value, duration is the one most frequently 
used in discussing disorders of vision. Episodes may 
vary in duration from seconds to as long as months 
(Fig 1 ). 
A no less important element is the laterality of 
Correspondence and reprint requests to Dr. John W . Harbi-
son , Department of Neurology , Box 698, Medical College of Vir-
ginia, Richmond , Virginia 23298. 
* Webster' s Third New International Dictionary. Springfield , 
G & C Merriam Co , 1971. 
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the visual event. Laterality is obviously restricted to 
right or left, a fact, however, which does not detract 
from its localizing value. Apart from laterality, yet 
closely related, is a further obvious fact: The eyes 
may be episodically involved independently or simul-
taneously . This too has great localizing value. 
The entities that produce episodic visual distur-
bance will be considered in sequence of timing, begin-
ning with those of brief duration and progressing to 
those of prolonged duration. Within each specific 
time unit the importance of laterality will be consid-
ered. 
Visual Disturbances Lasting Seconds. 
Obscurations. An obscuration is a brief altera-
tion of vision. It may occur monocularly, but gener-
ally it is binocular. It usually lasts from 5 to 10 
seconds, but it may continue for up to 30 seconds 
(Fig 2). Obscurations are usually frequent, occurring 
numerous times weekly if not daily. They may con-
Fig I-Graphic display of the time durations of all episodic dis-
orders of vision. 
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Fig 2-Graphic display of the time duration range of obscurations. 
tinue over extended periods, their ultimate duration 
depending upon the course of the inciting illness. 
They seem to be infrequently brought on by posture 
or activity and are classically unpredictable. 
A variety of terms are used in patient descrip-
tions of obscurations. A popular description is that of 
" ... a graying out of vision." ' They are also called 
blackouts, fade outs, and simply blurring. They have 
been compared to fog, mist, and opaque curtains. 
Obscuratio ns are usually isolated events, unasso-
ciated with other neurologic or visual symptoms. Be-
cause of their very brief durations, they are less 
alarming than other episodic disturbances of vision. 
Two causes of obscurations are presently recog-
nized : Papillede ma and vertebra-basilar in-
sufficiency."2 The differentiation of these two sources 
is simple and rests almost entirely upon the presence 
or absence of papilledema. 
Fig 3-Example of severe papilledema resulting in obscurations. 
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When obscurations result from papilledema, the 
optic disc changes are nearly always severe (Fig 3). 
The obscurations of papilledema may be monocular 
or binocular. Their origin is presumed to be ischemia 
of the optic disc, secondary to the increased in-
tracranial pressure. It is common to find additional 
signs and symptoms of increased intracranial pres-
sure in patients presenting with obscurations of pap-
illedema. These include headache, nausea and vom-
iting, and often diplopia. The incidence of focal 
neurologic signs is much less common and when pres-
ent ominously suggests a mass lesion. Most patients 
in this group are young, reflecti ng the possibly single 
most frequent etiology of the increased intracranial 
pressure-pseudotumor cerebri. . 
Patients presenting with obscurations as a mani-
festation of vertebra-basilar insufficiency are, not sur-
prisingly, much older. Here, obscur.ations are al.w~ys 
bilateral and imply bilateral ischemia of the occ1p1tal 
cortex. Obscurations may be the only manifestation 
of transient ischemia in the vertebra-basilar arterial 
distribution , or they may be one of many. Other 
manifestations include dizziness, diplopia, facial pa-
resthesias, dysarthria, weakness, and ataxia. These 
symptoms most commonly occur independently. Al-
though they may presage a stroke in the vertebro-
basilar arterial distribution, this relationship is 
unpredictable. Patients with obscurations of vertebro-
basilar origin never have papilledema. 
Obscurations per se are merely of diagnostic 
value and do not require treatment. Although papill-
edema may progress to blindness and optic atrophy 
the obscurations themselves do not reflect what the 
ultimate visual status will be. 
Treatment should be directed at the etiology of 
the obscurations. In those associated with papille-
dema, a mass lesion must be ruled out or pseudo-
tumor cerebri confirmed. Appropriate and specific 
therapy may then be initiated. If the obscuration is of 
vertebra-basilar origin, one must frequently evaluate 
the propriety of anticoagulation. In both circum-
stances appropria te therapy usually results in symp-
tomatic resolution. 
Visual Disturbances Lasting Minutes. 
In differentiating the causes of episodic distur-
bances of vision lasting for minutes, discrete dura-
tion and laterality are of paramount importance. 
Amaurosis Fugax. When the transient loss of 
vision occurs monocularly it is popularly referred to 
as amaurosis fugax-fleeting blindness.3 - 8 This clini-
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ca l event is characteristically of abrupt onset; it sel-
dom evolves in a progressive fashion. Its duration 
may be variable, lasting from one to several minutes , 
but the mode seems to be from one to three minutes 
(Fig 4) . It is often difficult to establish the time se-
quence as concretely as one would like, since patients 
frequently lose the perspective and scale of time. The 
degree of visual loss varies from complete to only 
moderate blurring, and altitudinal visual loss is not 
infrequent. A sensation of color may accompany the 
visual loss, but photopsia or scintillations are rare. 
The resolution of the visual disturbance is generally 
as abrupt as its onset and usually complete without 
residual loss of acuity or field . 
The episodes may recur many times per day or 
be separated by days , weeks, or months. They typi-
cally occur in isolation without associated neurologic 
symptoms, although additional transient signs of in-
ternal carotid ischemia such as hemiparesis, sensory 
change, and aphasia may occur independently . 
The overwhelming majority of patients present-
ing with amaurosis fugax will harbor extracranial 
internal carotid artery disease of atherosclerotic ori-
gin with precise localization to the common carotid 
bifurcation (Fig 5). Although amaurosis fugax may 
be "the hallmark of carotid insufficiency," a wide 
variety of other sources exists. These include increased 
intraocular pressure; that is, glaucoma, arteritis of 
the branches of the ophthalmic artery; g ian t ce ll or 
temporal arteritis, alteration of numerous elements o f 
the blood, red cells and proteins particularly , and 
thromboembolic events of cardiac o rigin such as 
mural thrombi, valvular vegetation of infectious or 
noninfectious origin, and tumor emboli. 
Fig 4-Graphic display of the time duration ran ge o f amaurosis 
fugax. 
101 
Fig 5- Lateral angiograp hic demonstration of ex tracra nial inter-
na l carotid a therosc leroti c disease (arro•v) productive o f a maurosis 
f ugax. 
As by far the most common etiology of amau-
rosis fugax is atherosclerotic disease of the carotid 
bifun.:at ion, it is appropriate to direct diagnostic con-
sideration to this focus. 
The presence of a focal bruit over the carotid 
bifurcation at the angle of the jaw has been found to 
be strong evidence of disease . A bruit , however, may 
not be present even with significant disease and occa-
sionally it may be falsely localizing with the signifi-
cant changes occurring in the contralateral carotid. 
Asymptomatic bruits, although evidence of some de-
gree of disease , should rarely be pursued diagnos-
tically . 
C hanges in the ca rotid pulsation in the neck are 
seldom helpful. Often the external carotid overlies the 
internal carotid and masks changes in the latter ves-
sel's pulsation. 
Single or multiple bright refractile cholesterol 
emboli found in the ipsilateral retinal arterioles are 
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Fig 6-Fundus photograph of cholesterol emboli (arrows) . 
strongly indicative of a carotid o rigin for amaurosis 
fugax. 9 •10 Less apparent whitish platelet plugs may 
a lso be seen. These emboli often lodge in bifurcations 
of vessels distal from the optic disc, thus requiring 
pupillary dilatation and careful funduscopic exam-
ination for identification (Fig 6). 
The use of ophthalmodynamometry, Doppler 
flow studies, and thermography provide additional 
pieces of incriminating evidence. It remains, however, 
for carotid angiogra phy to confirm the presence, ex-
tent , and significance of bifurcation atherosclerotic 
cha nges (See Fig 5). 
The identification of the other less common 
causes of a maurosis fugax is seldom difficult if their 
possibility is recognized. 
Treatment should be directed at the cause o f the 
Fig 7-Fundus photograph of cloudy retinal edema (arrow) sec-
ondary to a central retinal artery branch occlusion with infarction. 
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Fig 8-Graphic display of the time duration range o f migraine. 
amaurosis fugax. A significa nt incidence of stroke in 
the interna l carotid a rtery distribution including the 
retina follows premonitory amaurosis fugax (Fig 7) . 
In carotid bifurcation atherosclerotic disease we at 
the Medical College of Virginia have favored en-
da rterectomy when appropriate. The primary ob-
stacle to endarterectomy has been significant symp-
tomatic cardiac disease. In this situation, anticoagu-
lation may be advisable . 
Migraine. Typical amaurosis fugax which con-
sisten tly lasts from IO to 30 minutes should suggest 
the likelihood of a migrainous origin (Fig 8). 
The recognition of visual phenomena as the fore-
runner of migraine dates to antiquity11 ; t he variety of 
these visual hallucinations is remarka ble.12•13 It is a lso 
clear that the visual aura may constitute the sole mani-
festation of a migraine attack.14 If indeed the visual 
aura is never followed by the hemicranial, vascular 
headache, nausea, and diffuse autonomic disturbance, 
one may have difficulty in recognizing its migrainous 
character. That this specific circumstance mimics 
ama urosis fugax seems well established.14 Certain fea-
tures of the clinical presentation are useful in identify-
ing these admittedly uncommon cases of migraine. 
Typically, the event recurs in an identical fashion 
over many years. It commonly begins under the age 
of 20. The expected heredita ry aspect of migraine is 
frequently a bsent and the relationship of the visual 
event to the headache may become so inconstant as 
to appear to have no connection-so-called dis-
sociated migraine. In some cases, headache may 
never occur. The most important feature, however, 
remains the duration . A maurosis fugax as a manifes-
tation of complicated migraine almost always lasts 
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between 10 and 30 minutes. It is comrr 
presentation to resolve as the patient ac 
the 20's and 30's and be replaced by r 
migraine. 
Vertebra-basilar Insufficiency. Whe 
loss of vision of minutes in duration occu1 
the source most commonly is in the vert 
arterial distribution. 2 Although amauro 
internal carotid origin conceivably might 
erally and synchronously, this must ind 
Obscurations, the momentary visual loss 
onds cf ue to vertebra-basilar insufficienc 
discussed above. More commonly, ho1 
sient visual loss secondary to ischemia 
tebro-basilar distribution lasts one to fi 
With the increase in duration of the vi: 
ment, patient concern is, understanda 
cantly increased. This in itself may ace< 
greater frequency with which these vist 
reach the physician's attention. The e' 
visual loss is variable from a simple per• 
of central vision to total blackout. 
In common with patients presenting 
rations of vertebra-basilar origin, this p: 
tends to be elderly. The association o 
symptoms of brain stem origin occurring 
pendently or synchronously is to be antic 
would again expect historical evidence 
dizziness, vertigo, diplopia, dysarthria, a 
and bilateral extremities paresthesias as"' 
ness. 
The implied risk of stroke in the vert 
arterial distribution in this patient group 
those manifested simply by obscuratio 
eration of anticoagulation is appropriat 
few highly selected patients presenting < 
history of symptom precipitation by nee 
or position and confirmed by angiogr: 
surgery directed at decompression of C• 
vertebral arteries in the cervical spine m< 
ered (Fig 9). This patient population is t 
nificantly younger than the average patit 
tebro-basilar insufficiency, and frequent!) 
trauma is clearly evident. 
Basilar Artery Migraine. In a mann 
amaurosis fugax, when transient bilater: 
pairment occurs with a duration of frc 
minutes, a migrainous etiology becomes 
(See Fig 8). 
Basilar artery migraine has been wel 
and adequately described for some tim 
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ig 9-Subtracted lateral view of a vertebral angiogram demon-
rating arterial compromise (arrow) by osteoarthritis in the cer-
eal spine, which resulted in visual loss. 
iarked tendency to occur in a recognizable pattern. 
t is most common in adolescent girls. Visual symp-
Jms are the most common initial event with the 
isual disturbance varying from total loss of vision to 
lurring of central vision. Positive visual manifesta-
ons characteristic of migraine may be totally absent. 
.ssociated vertigo, ataxia, dysarthria, and sensory 
aresthesias are common. Characteristically, a severe 
hrobbing occipital headache often accompanied by 
ausea and vomiting follows. As with the migrainous 
maurosis fugax, however, headache may not occur. 
Generally the clinical pattern is such that doubts 
.f its migrainous origin do not arise. Once again 
here is a tendency for these attacks to be replaced by 
10re classic migraine as the years pass. 
Visual Disturbance Lasting Hours. 
Episodic disturbance of vision lasting hours 
eems to be less often recognized if not actually less 
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Fig JO-Graphic display of the time duration range of episodic 
visual loss secondary to uncontrolled diabetes mellitus. 
common. Some of the sources of visual symptoms 
measured in hours are extensions of previously dis-
cussed entities. Some, however, are entirely new and 
distinct. 
Diabetes M ellitus. The incidence of episodic vis-
ual disturbance lasting hours in diabetes mellitus is 
unclear (Fig 10). It is quite likely that early diagnosis 
and improved drug control has significantly reduced 
the magnitude of these visua l symptoms if not their 
incidence. 
Sudden bilateral blurring of vision is well known 
to occur in patients with diabetes mellitus.'6 •17 It has 
on occasion been the initial symptom leading directly 
to the diagnosis in a previously unrecognized case. 
More commonly it occurs in established diabetic 
patients; its basis is known to be abrupt refractive 
changes in the eye of either myopic or, hypermetropic 
nature. The refractive change seems rather clearly 
related to blood sugar levels; myopia occurring in the 
presence of hyperglycemia a nd hypermetropia with 
hypoglycemia. It may, in fact, be useful in alerting the 
physician to ineffective diabetic control. 
The visual disturbance is described by the 
patient as blurring with impairment of central vision. 
In all circumstances it can be corrected by appropri-
ate refraction . At the bedside the use of a pinhole 
may prove the refractive nature of the visual change 
to the satisfaction of the physician . 
The precise mechanism by which the blood sugar 
level effects the abrupt refractive change is not en-
tirely clear . It i ~ postulated, however, to be the result 
of secondary changes of lens hydration. 
The course of visual blurring in poorly con-
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trolled diabetics is transitory, lasting variable peri-
ods, usually measured in hours to a few days . It is 
<:!lmost invariably reversible. Occasionally cataracts 
may develop abruptly in this group of patients.17 
Therapy of this episodic visual disturbance 
should be directed at more effective diabetic control 
rather than refractive correction by virtue of its tran-
sitory nature. 
Post-traumatic Blindness. A second transient 
visual disturbance typically lasting hours which al-
though probably uncommon is often unrecognized is 
post-traumatic or concussion blindness (Fig 11 ). 
This transient bilateral visual loss seems clearly 
of occipital cortical origin. It is also quite certainly 
causally related to preceding head trauma. Children 
appear to be much more susceptible to post-trau-
matic blindness than adults. 18·!9IPP23s• - 23851 The degree 
of trauma necessary for the manifestation of this 
syndrome is markedly less in children where rela-
tively minor head injury, usua lly occipital in nature, 
and unassociated with unconsciousness or skull frac-
ture, has resulted in post-traumatic blindness. In 
adults the injury is frequently much more severe with 
unconsciousness and skull fracture the rule. 
The visual disturbance is commonly severe with 
early tota l loss no t unusual. The course of recovery is 
similar in both children and adults; there is generally 
progressive return of vision to normal over a period 
of from one to three hours. Permanent residual dis-
turbance may or may not occur and generally reflects 
the magnitude of the occipital injury. The currently 
accepted mechanism of visual loss is felt to be occi-
Fig I I-Graphic display of the time duration range of post-trau-
matic visual loss. 
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Fig 12-Graphic display of the time duration range of episodic 
visual loss secondary to stroke. 
pita! lobe-visual cortex concussion. Treatment is usu-
ally expectant requiring only observation. 
Stroke. Final consideration in visual distur-
bances lasting hours should be given to those episodic 
disorders of vision previously discussed where the 
transient ischemia, whether localized to retinal ves-
sels, internal carotid artery, or vertebra-basilar sys-
tem, whether of atherosclerotic, systemic, or migra-
inous origin, ceases to be transient and results in 
more prolonged visual deficit (Fig 12). 
An arbitrary point has been established at 24 
hours which is used to separate transient ischemic 
attacks from strokes. As with most other artificial 
guidelines, much variation occurs in clinical practice. 
We therefore regularly classify as strokes events 
which last from 12 to 24 hours to three and more 
days. 
Common to the majority of these events is a 
history of preceding episodes of transient visual dis-
order. These include obscurations, 2 amaurosis fugax, 8 
and transient cortical visual loss,3 as well as classical 
migrainous events of either monocular or binocular 
character.12 Not infrequently, although resolution 
may be nearly complete, residual loss of visual acuity 
or field may remain, emphasizing that a stroke has 
occurred. 
Retinal strokes basically consist of central reti-
nal artery and central retinal artery branch occlu-
sion.9 The latter is obviously the most frequent retinal 
stroke to resolve. 
The onset is classically abrupt with complete 
monocular visual loss. Characteristic of these events 
is funduscopic evidence of retinal ischemia. This usu-
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ally is greyish retinal edema stopping short of the 
classic cherry-red spot of irreversible central retinal 
artery occlusion (See Fig 7). Recovery often begins 
within an hour or so and evolves over several hours . 
Residual visual acuity changes may vary from slight 
to severe and visual field changes are characterized 
most commonly by altitudinal or sector field loss. 
Treatment should be directed toward the usually 
neglected internal carotid bifurcation disease (See Fig 
5). Prompt therapy may avoid a tragic repetition 
resulting in permanent blindness. 
Total occlusion of the cervical internal carotid 
artery at its bifurcation with the external carotid may 
result in a wide variety of clinical manifestations. On 
the one hand, a devastating hemisphere infarct with 
hemiplegia and aphasia may occur; on the other, the 
patient may note only the transfer of his odd, neck 
bruit from one side to the other and cessation of the 
bothersome episodes of transient monocular blind-
ness. Between these two extrem~s, an episode of pro-
longed visual impairment of hours' to days' duration 
may occur. The clinical picture may so resemble that 
described for retinal strokes as to defy separation. 
Of significant value in placing the inciting event 
in the internal carotid artery is the reversed bruit and 
an ipsilateral Horner's syndrome (Fig 13 ). 
It is quite common for the focal bruit of internal 
carotid bifurcation disease to cease with occlusion of 
the artery. It is likewise frequent fo r a focal "in-
creased flow bruit" to be either accentuated or be-
come initially manifest over the contralateral internal 
carotid bifurcation. At the same time, in about 15% 
of internal carotid occlusions, edema of the arterial 
Fig 13-Right-sided miosis and ptosis of Homer's syndrome sec-
ondary to internal carotid artery occlusion. 
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Fig 14-Graphic display of the time duration range of optic neu-
ritis. 
wall involves the vasa vasorum of the carotid sympa-
thetic plexus resulting in an ipsilateral Homer's syn-
drome characterized by miosis and ptosis without 
anhidrosis (See Fig 13 ). The other clinical hallmarks, 
as with retinal stroke, may consist of funduscopically 
visible retinal edema, variable visual acuity loss, and 
field defects of attitudinal or sector character. 
Diagnostic confirmation is angiographic. U nfor-
tunately, therapy is ineffective, emphasizing the need 
of early clinical recognition of internal carotid arte-
rial disease. 
Strokes in the vertebra-basilar arterial distribu-
tion regularly result in prolonged visual loss lasting 
hours to days. Restitution of some visual function, 
however, is the rule. The association of additional 
neurologic deficit of brain stem and cerebellar origin 
is highly variable. 
The onset of the bilateral visual loss is similar to 
a transient ischemic attack, which commonly has pre-
ceded the stroke by days to months. On this occasion, 
however-, the vision does not improve promptly and 
blindness remains . Characteristically, vision begins to 
return in hours to a few days. In this time period the 
patient may experience a variety of visual phenomena 
including either crude or complex visual hallucina-
tions and visual distortion. 
Visual acuity not infrequently achieves remark-
able recovery. Residual visual field defects of ho-
monymous character, either hemianopic or quad-
rantinopic are frequent. It is not unusual for the 
patient to experience enduring visual agnosias of di-
verse nature including color-naming defects, and ag-
nosias for faces, places, and even food. 
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Treatment again should be directed at pre-
vention of repetitive strokes with anticoagulation, the 
most popular if not the most effective therapy. 
The occurrence of permanent residual defects of 
vision following typical complicated migraine in-
volving retinal , carotid, or basilar arterial distribu-
tions is well established, although rare. 12 The clinical 
circumstance is readily recognized by the presence of 
a long history of preceding typical repetitive episodes 
of visual disturbance suggesting a migrainous basis. 
The mechanism whereby a benign migrainous event 
is transformed into a permanent stroke is unclear. 
Therapy has been ineffective. 
Visual Disturbance Lasting Days to Weeks. 
A discussion of episodic visual disturbance last-
ing days to weeks becomes essentially a discussion of 
optic neuritis (Fig 14 ). There are unusual exceptions 
to this dictum which will be discussed subsequently. 
Optic Neuritis. Optic neuritis is a misleading 
term. Its implication of an infectious or inflammatory 
basis of optic nerve disease is rarely accurate. Al-
though bacterial and viral disease of the central ner-
vous system and orbital contents occasionally results 
in optic nerve dysfunction, the ciinical picture does 
not correspond in most circumstances with the gen-
eral definition of optic neuritis. The systemic symp-
tomatology, clear evidence of inflammatory orbital 
or central nervous system (CNS) disease as well as a 
more fulminant, frequently irreversible optic nerve 
injury, generally serve to distinguish this truly in-
fectious optic neuritis from the more common clinical 
picture. 
The clinical definition commonly used for optic 
neuritis is that of rapidly developing blurring of vi-
sion with or without pain about the eye or on move-
ment of the eye.20•21 It may occur either monocularly 
or binocularly. There is a tendency for binocular 
involvement to be most frequent in children.22 The 
degree of visual loss is variable; however, loss of 
central acuity greater than 20/ 200 is the rule. The eye 
is normal on examination. Visual field evaluation 
should demonstrate field loss, most commonly in the 
form of a central scotoma. The funduscopic exam-
ination may be normal or reveal disc swelling and 
elevation with or without hemorrhages and exl.idates. 
Disc pallor is rare and if present should suggest pre-
vious bouts of optic neuritis whether or not a con-
firmatory history is available. Optic neuritis most 
commonly occurs in isolation without associated 
neurologic symptoms or signs. 
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The episode of optic nerve dysfunction tends to 
last from a few weeks to a few months. Total resolu-
tion is not uncommon, particularly from an acuity 
standpoint, but mild residual defects are not in-
frequent. Further episodes occur in a minority of 
cases, but may do so on multiple occasions. 
The age of onset of optic neuritis varies tremen-
dously from the pre-teens to the 70's and, rarely , 
80's.23 The median age in most studies has been about 
30. 
Optic neuritis has been characteristically classi-
fied as either typical ·or atypical. The typical patient is 
a young patient generally in the 20's, fulfilling rather 
closely the criteria already presented, with monocular 
involvement. The atypical patient generally falls out-
side the 20- to 40-year age group, and develops visual 
loss in either an abrupt fashion or progressively at a 
slower pace. Visual acuity is either insignificantly in-
volved or severly impaired . Commonly, the episode 
of visual disturbance fails to remit or does so very 
incompletely in the expected period of days to 
weeks. Associated symptoms and signs of neurologic 
or medical disease are distinctly more frequent. 
Within that group of patients with optic neuritis 
characterized as typical is a second subdivision. This 
is based upon the presence or absence fundusco-
pically of disc edema and elevation . In the absence of 
disc changes, the optic neuritis is termed retrobulbar 
neuritis. In its presence, the optic neuritis becomes 
papillitis. This designation has little if any implication 
with regard to etiology or prognosis.20 
If a specific etiology is not identified, it is com-
mon to assume that the optic neuritis is a harbinger 
of multiple sclerosis. Sufficient long-term studies are 
available to place the association of optic neuritis and 
multiple sclerosis in true perspective. It is now rela-
tively clear that only one in six patients with optic 
neuritis can be expected to develop typical multiple 
sclerosis in the future. 20·21 This incidence of about 
15% is significantly lower than prior incidence rates 
frequently placed nearer 50%.24·25 Armed with this 
reduced statistical probability the physician can re-
frain from a discussion of multiple sclerosis and the 
psychological impact it carries with a much clearer 
conscience. 
The potential etiology of remaining cases of op-
tic neuritis is legion and virtually reads as an index of 
medical and neurologic disease.23 Not surprisingly, 
however, a very substantial number of cases of typi-
cal optic neuritis remain of so-called idiopathic ori-
gin. 
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The identification of those cases of optic neuritis 
for which a firm etiology can be achieved is fre-
quently linked to a more atypical presentation: bi-
nocular instead of monocular involvement; a young 
or elderly patient; and, perhaps most importantly, the 
association of additional medical or neurologic signs 
or symptoms. 
The treatment of optic neuritis, typical or atypi-
cal, has been , and remains, an area of controversy. 
Obviously if a specific inciting etiology can be identi-
fied, therapy should be based on the diagnosis. In 
those cases classified as idiopathic, as well as those 
suspected to be premonitory of multiple sclerosis, it 
has been common to use adrenal corticosteroids; 
their efficacy remains controversial and many com-
petent physicians do not use them. When adrenal 
corticosteroids are used, it is common to begin with 
a high dose, from 60 to 100 mg daily, and follow a 
rapidly tapering course over two to three weeks. 
Little if any difference in efficacy has been detected 
with the preparation used or the mode of administra-
tion. Prednisone, an inexpensive preparation taken 
orally, a simple painless mode of administration, is 
not an unreasonable approach if one wishes to treat a , 
given patient. 
A diagnostic pitfall occurs in a group of the 
atypical optic neuritis cases based upon their occa-
sional response to adrenal corticosteroid therapy. 
Cases of optic neuritis ultimately found to be caused 
by sarcoidosis, meningioma, pituitary adenoma, and 
carcinomatous leptomeningitis may occasionally im-
prove dramatically with steroids. This has led to diag-
nostic errors. In nearly every instance the optic neur-
itis has been atypical. Thus atypical features in optic 
neuritis should suggest diagnostic caution. 
The typical course of optic neuritis has been one 
of resolution with or without a residual defect of 
variable nature and degree in from a few days to 
many weeks . Treatment with adrenal corticosteroids 
has been believed capable of hastening resolution but 
probably incapable of improving final function. 
Post-epileptic Blindness. One final cause of epi-
sodic visual disturbance lasting from days to weeks is 
postictal amaurosis (Fig 15). Although this particular 
clinical entity occurs rarely, its occurrence can cause 
extreme consternation if the etiologic mechanism or 
association is unrecognized. 
Postictal amaurosis of cortical origin has been 
repeatedly observed in young children and in-
fants.191vv121 - 1291·26 The convulsive episode has typi-
cally been violent. The blindness may be associated 
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Fig 15- Graphic display of the time duration range of post -
epileptic blindness. 
with aphasia, deafness, or hemiplegia . Visual loss has 
typically lasted from days to weeks with slow, pro-
gressive recovery . The mechanism of its production 
remains unclear. No satisfactory therapy has been 
identified. 
Summary. 
A diverse and seemingly unrelated group of dis-
eases has been integrated on the basis of their epi-
sodic disturbance of vision. The parameters of later-
ality, but more importantly the duration of individual 
,episodes, have been used to direct diagnostic consid-
eration. Many of these clinical entities are commonly 
encountered in practice. Their recognition and care 
are dependent upon prompt diagnosis based upon 
characteristic clinical signs and symptoms. 
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An Approach to Dizziness 
ALAN B. GRINDAL, M.D. 
Assistant Professor, Department of Neurology, Medical College of Virginia , H ea/th Sciences Division of Virginia 
Commonwealth University, R ichmond, Virginia 
Dizziness is a vague and ubiquitous sym ptom 
which frequently frustrates and perplexes the clini-
cian . Dizz iness in the broad sense implies any un-
pleasant sensa tion of di sturbed relation ship to sur-
rounding objects. A number of sy non yms such as 
faintness, light-headedness. gi ddiness, a nd swaying, 
although descr iptive . are often no more speci fic. 
Problems in diagnosis , therefore, are due not only 
to the arn biguity of the term but also to the wide 
spectrum of disorders in which di zzi ness m ay be a 
prominent symptom. Although disorders of the ves-
tibular system usually receive primary attention, it 
should be kept in mind that many neurologic, cardio-
vascular, p sychiatric, and other disorders a re not in-
frequently associated with dizziness. 
The term ver tigo, on the o ther hand, is specific 
and may be distinguished from other forms of di zzi-
ness in th a t it implies a definite rotational sensation 
or illusion of motion. Although it is often impossible 
to make a differentiation between vertigo a nd other 
types of dizziness in the individual patient. the dis-
tinction is important as vertigo specifically reAects 
dysfunction in the vestibular system. 
The purpose of this paper is to review the anat-
omy and physiology of the vestibular system, to dis-
cuss the most common clinically significant causes of 
di zziness, and finally , to consider the practical office 
evaluation of the dizzy patient. 
The Vestibular System. A bas ic understa nding of 
the anatomy and physiology of the vestibular system 
is necessary in order to understand the procedures 
employed to test its integrity as well as the clinical 
Correspondence a nd reprint req uests to: Dr. A Ia n B. Grindal , 
Derartment of Neurology , Box 698, M edical College of Virginia. 
Richmond. Virginia 23298. 
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ma nifestation of its dysfunction. The vestibular sys-
tem includes the end organ (semicircular canals and 
otolith system), a portion of the eighth cranial nerve, 
and the vestibular nuclei in the brain stem. 1 Fibers 
from the ves tibular nuclei project to the cerebellum, 
skeletal muscula ture, extraocular musc les, and un -
doubtedly to the cerebrum. The precise connections 
to the cortex are unknown , although vestibular repre-
sentation in the posterior temporal lobes is suspected. 
The vestibul ar apparatus serves as the primary organ 
of eq uilibrium comb ining with visual and other sen-
sory stimuli to provide sensa tion of motion and spa-
tial orientation . The vestibular system also functions 
in the control of skeletal muscle ton us and in stabiliz-
in g the eyes during head movements . In the steady 
state, there is equal tonic neura l input from the two 
end o rgan s. With rotation a l movement, the semi-
circu lar cana l in the plane o f movement is stimulated , 
leading to a change of neural activity in the brain 
stem, which is projected to the cortex to produce the 
appropriate conscious sense of rotation . A disease 
sta te which changes the firing frequency of the end 
organ , or the neural input from the brain stem , causes 
ver tigo. In such cases the cerebral cortex is seemingly 
deceived by the brain stem input and interprets it as 
rotational movement. 2 
Vestibular dysfunction may be classified as pe-
ripheral or central , the dividing line being where the 
eighth nerve enters the brain stem. Peripheral disease 
is generally felt to be most common and is not in-
frequently associated with a hea ring disturbance due 
to the close anatomical relationship between cochlear 
and vestibular portions of the inner ear. A patient 
with unidirectional jerk nystagmus, vertigo in the di-
rection of the first component, past pointing, and fall-
ing in the direction of the slow component is prob-
ably suffering from acute dysfunction of the end 
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organ on the side of the slow phase. Bidirectional 
nystagmus varying with direction of gaze, vertical 
spontaneous nystagmus, past pointing, and falling 
toward the fast phase points to brain stem disease. 2 
Vertigo is usually more intense with peripheral dis-
orders and is commonly associated with nausea and 
vomiting. 
Positional vertigo refers to the vertigo and ac-
companying nystagmus which occurs after the head is 
placed in a particular plane. Peripheral and central 
forms of positional vertigo have also been described, 
based on the characteristics of the nystagmus in-
duced.2 In the peripheral type, a latency of 3 to 40 
seconds is observed between attaining the precipi-
tating head position and the onset of nystagmus. If 
the head remains in this position , the nystagmus will 
decrease or fatigue after 30 to 60 seconds. Gradual 
habituation of the nystagmus occurs with repetition 
of the aggravating position and reproducibility is 
poor at any given examination. With central pathol-
ogy, the onset of nystagmus is immediate and fatigue 
and habituation do not occur. Again, vertigo is gen-
erally more severe with peripheral disorders. 
Otolaryngologic Causes of Dizziness. A variety of 
otologic disorders ranging from impacted cerumen, 
and otitis media to otosclerosis and trauma to the 
labyrinths may produce dizziness. This discussion 
will be limited to the more common and clinically 
significant disorders . 
Meniere's disease or endolymphatic hydrops is 
predominantly a disease of middle-age or older, and 
is unilateral in 90% of cases. The onset is usually 
insidious, frequently beginning with tinnitus, fullness 
in the ears, and Auctuating hearing loss. The hall-
mark of the disease is episodic vertiginous spells usu-
ally lasting between 2 and 24 hours. During the at-
tack, pain or numbness may be noted in the affected 
ear as well as diminution of auditory acuity. Spells 
recur at irregular intervals varying from days to 
years .a 
The majority of patients with positional vertigo 
suffer from benign positional vertigo.4 In this type, 
hearing and caloric responses are normal and tran-
sient symptoms occur only with assumption of acer-
tain head position. The greatest incidence is between 
40 and 60 years of age and symptoms often clear 
spontaneously within one year. The etiology is un-
known. 
Acute labyrinthitis may occur as a result of acute 
or chronic otitis media and is manifested by vertigo, 
nyst,agmus, severe hearing loss, nausea, and vomit-
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ing . Toxic labyrinthitis is usually secondary to oto-
toxic antibiotics such as streptomycin. Typical ver-
tigo may not occur since both labyrinths are equally 
depressed. The primary manifestation may be diffi-
culty walking with staggering and inability to stay on 
course. Hearing loss and high-pitched tinnitus may or 
may not occur. 
Vestibular neuronitis or viral labyrinthitis is pri-
marily a disease of young adults which frequently 
exists in epidemic form. This disease may be defined 
as a sudden vestibular crisis lasting days or weeks 
with partial or total loss of vestibular function in one 
ear without auditory involvement, and without recur-
rence.a The prolonged period of the attack and the 
absence of hearing loss and recurrence distinguish 
vestibular neuronitis from Meniere's disease. 
Neurologic Causes of Dizziness. A caustic neu-
romas are the most common of the cerebellopontine 
angle tumors comprising approximately 5% of all 
intracranial tumors. Early symptoms are usually ves-
tibular and cochlear, but the latter usually appear 
first. The onset of unilateral high-frequency hearing 
loss and high-pitched tinnitus is often insidious. Ver-
tigo is usually not a prominent symptom and most 
patients complain of transitory, but progressive, 
vague dizziness and unsteadiness which is aggravated 
by movement. 5 This may be explained by the slow 
expansion of the tumor which allows time for the 
vestibular nuclei to compensate for the disturbance. 6 
Associated signs of involvement of the seventh, sixth, 
and fifth cranial nerves and cerebellum are usually 
late, although such signs should be sought and are 
diagnostic when present. 
Although the sudden onset of dizziness is a fre-
quent symptom of vertebra-basilar cerebrovascular 
disease, it rarely occurs in isolation without other 
symptoms of neurologic dysfunction such as dip-
lopia, dysarthria, facial numbness, or hemiparesis. 
C. M. Fisher points out that dizzy spells that con-
tinue more than six weeks without accompanying 
symptoms are almost never cerebrovascular in na-
ture.7 There seems to be an unwarranted tendency to 
attribute mild giddy spells in elderly persons to 
"hardening of the arteries. " 
Dizziness is a frequent and often early symptom 
in multiple sclerosis. Like cerebrovascular disease, 
however, other signs and symptoms such as visual 
blurring, diplopia, ataxia, paresis, and paresthesias 
are almost always present. According to some au-
thors, multiple sclerosis is the most common cause of 
the central type of positional nystagmus.6 A unique 
112 
feature in this di sease is the frequent di ssociation of 
vertigo and nystag mus. 
Vertiginous symptoms may occur as icta l phe-
nomena in patients with seizures of temporal lobe 
origin. In such cases consciousness is usua lly im-
paired, momenta ry amnesia is often noted , and nys-
tagmus does not occur. Some patients complain of 
being hurled into space as if in a tornado. 
Cardiovascular Causes of Dizziness. The cardio-
vascular causes o f di zziness have in common the pro-
ductio n o f symptoms by arrest o r d iminution of cere-
bral perfusion. With orthostatic hypotension, the 
patient experiences light-headedness, unsteadiness, 
a nd occasionally syncope upon suddenly assuming an 
erect position. This syndrome may be idiopathic, 
however, it is often secondary to prolonged bed con-
finement , a nti-h ypertensive agents , or impairment of 
sympathetic vasomotor reflex activity . Such a ttacks 
a re usua lly accompanied by pa llo r, tachyca rdia, a nd 
sweating as well as the obvious drop in blood pres-
sure. Cardiac disorders ranging from mechanical ob-
struction to .alterations in cardiac rate or rhythm cari 
impair cerebral blood flow and may produce vertigo 
and dizziness. In aortic stenosis, the o nset of symp-
tom s is usua ll y related to sudden position change . In 
addition, a lmost a ny a rrhythmia may produce ver-
t igo and dizziness . The patient may state in such cases 
that his dizzy episode is associated with a detectable 
change in cardiac rhythm. Overactive autonomic re-
fle~es may also result in dizziness followed by syn-
cope. Hypotensio n a nd bradyca rdia may be triggered 
by an emotional or pa inful stimulus as in vasovagal 
syncope or be precipitated by micturition , pa roxys-
ma l coughing, o r compression of the carotid sinus in 
the neck. An impending feeling of syncope character-
izes di zziness of cardiovascular etiology. 
Anemia and hypoglycemia should 'also be consid-
ered among the systemic causes of dizziness. 
Other Causes of Dizziness. Dizziness is a com-
m o n symptom in psychiatric diso rders. These 
patien ts usually complain of a vague sensation of 
light-headedness, which tends to be continuous 
rather than episodic and is associated with symptoms 
of anxiety, depression, or other hypochondriacal 
complaints. Hyperventilation syndrome is a very com-
mon cause o f dizziness. a nd the majority of these 
patients suffer from emotio na l problems. Acute a t-
tacks of hyperventila tio n produce relatively circum-
scribed episodes of light-headedness, frequently with 
circumoral and digital pa resthesias and tightness in 
the chest. Positional vertigo occurring o nly after hy-
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perventilation has also been reported .a The hypo-
capnia produced by hyperventilat ion leads to cere-
bral vasoconstrictio n and a reduction in cerebral 
blood fl ow. 
Drachman and H art described the occurrence o f 
dizziness a mong patients with multiple sensory defi-
cits. a The abnormalities comprising this syndrome 
consisted of two or more of the following: visual 
impairment (usually cataracts), peripheral neu-
ropathy, vestibular deficits, cervical spondylosis, and 
orthopedic a bnormalities interfering with ambula-
tion . Typically, pa tients were elderly dia betics, who 
only complained of light-headedness when walking 
and particularly when executing a turn . Dizziness in 
this group was most closely reproduced by walking 
and turning the head when standing. Drachman and 
Hart postulate that the deprivation of accurate sen-
sory information produces disorientation which is 
referred to as dizziness by its sufferers.a 
There is considerable disparity between studies 
rega rding the frequency of various causes of dizzi-
ness .6 Most reports deal with a selected and limited 
segment of the dizzy population . The data compiled 
by the Northwestern U niversity Dizziness C linic per-
haps best refl ect the incidence of various types o f 
dizziness in the genera l popula tio n.a This study con-
sisted of 125 pa tients with the compla int of di zziness 
of a ny type without any selection . A reasonably cer-
tain diagnosis was claimed in 91 % of cases (Table). 
Disorders of the peripheral vestibular system proved 
to be the most com mon cause of dizziness in this 
st udy . These patients co mplained of rotational ver-
tigo, freq uently associated with na usea and vomiting, 
occurring in the absence of evidence of neighboring 
brain stem deficits . Among the 38% of patients with 
peripheral vestibular disorders, benign positional ver-
tigo occurred twice as frequentl y as a ny other ves-
Table 
Major Causes of Dizziness* 
Periphera l Vestibular Disorders 
Hyperven tilation Synd rome 
M ultirle Sensory Deficit 
Psychiatric Disorders 
Uncertain Diagnosis 
Bra in stem Cerebrovascular 
Cardiovascular 
Neurologic Disorders (others) 
38% 
23% 
13% 
9% 
9% 
5% 
4% 
4% 
* Total is greater than 100% because several patients had more 
than o ne diagnosis. 
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tibular disorder. Meniere's disease and vestibular 
neuronitis each made up 4% of this total. Hyperventi-
lation and multiple sensory deficits together ac-
counted for over one third of the patients . The rela-
tive infrequency of cerebrovascular disease 
presenting with symptoms of dizziness is pointed out 
in the 5% figure . These patients , in keeping with 
C. Miller Fisher's statement ,7 all had evidence of 
additional neurologic involvement. The absence of 
cases of sei zure and acoustic neuroma indicates that 
these are rare but nonetheless important causes of 
dizziness . 
Evaluation. On the basis of the preceding dis-
cussion of the pathophysiology and causes of dizzi-
ness. we will now consider the clinical evaluation of 
the di zzy patient. Many sophisticated and expensive 
neurologic and otologic procedures are available. We 
shall concentrate, however, on practical office tech-
niques and on indications for specialist referral. 
The single most important aspect in the eval-
uation of a patient with dizziness is a good history, 
properly interpreted. Drachman and Hart8 have 
noted that the patient' s subjective experience of dizzi-
ness can often be separated into one of four types: 1) 
a definite rota tional sensation , 2) a sensation of im-
pending faint, 3) dysequilibrium or loss of balance 
with little or no head sensation, and 4) vague light-
headedness other than vertigo, syncope, or dysequili-
brium .8 Inquiries need to be made regarding precipi-
tating factors such as relation to posture and motion, 
the intermittency or constancy of symptoms, and as-
sociated symptoms such as hearing loss, tinnitus , 
nausea or vomiting, and loss of balance. 9 The occur-
rence of other otologic symptoms (discharge, full-
ness, or pain in ears) and neurologic symptoms such 
as disturbances of vision, speech, motor, and sensory 
function should be sought. Past medical history in-
cluding significant medical illnesses and use ·of medi-
cations must be obtained. 
In view of the wide variety of disorders in which 
di zziness may be present , a complete physical exam-
ination is necessary. In addition, special attention 
should be directed to certain aspects of the otologic 
and neurologic examination . The external auditory 
canal should be checked for impacted cerumen or 
other abnormalities, and the eardrum carefully exam-
ined for evidence of fluid level, hyperemia, bulging, 
or perforation . Disturbances of hearing may become 
evident during conversation with the patient. Atten-
tion should be paid to the level of voice required for 
communication, the need for repetition, and the de-
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gree to which lip reading is depended upon . Although 
not as sensitive as standard audiometry , the classic 
Weber and Rinne tests using an audiometric tuning 
fork in the 500 Hz range are most informative. Cer-
tain aspects of the neurologic examination should be 
emphasized . The patient should be observed for past 
pointing. In this test the patient stands, extends both 
arms, points with both index fingers at the examiner's 
index fingers held at shoulder height. and then closes 
his eyes. Drift of the hands consistently in either 
direction is abnormal. 6 With peripheral disease, the 
arms will deviate in the direction of the slow phase of 
the nystagmus. Peripheral disturbances will be aggra-
vated by testing the patient with his head inclined 
over one or the other shoulder. Past pointing in the 
direction of the fast phase or in the absence of nys-
tagmus indicates central vestibular pathology. 
Disturbances in gait and posture may be seen in 
patients with proprioceptive, cerebellar, and vestibu-
lar disorders. The Rom berg test is classically positive 
in patients with proprioceptive defects; the direction 
of falling is usually variable. With peripheral vestibu-
lar disease, the Romberg test is also positive: how-
ever, the direction of fall is consistently to one side 
and is influenced by changing the position of the 
head. Jn cerebellar disease, station and gait are not 
remarkably influenced by closing the eyes, and ataxia 
is generally in evidence. 
Because of the ever-present concern of the in-
sidious cerebellopontine angle tumor, careful exal]1-
ination of the fifth and seventh cranial nerves should 
be carried out. The symmetry and strength of the 
facial musculature and muscles of mastication need 
to be evaluated. The corneal reflex is simple to test 
and is most informative. While the patient is looking 
upward and to one side, the physician touches the 
cornea on the opposite side with a piece of cotton. If 
blinking is absent in both eyes, this indicates a loss of 
sensation in the cornea tested; if blinking is absent 
only in the eye tested, the homolateral facial nerve 
may be impaired. Impairment of the homolateral 
corneal reflex is frequently noted in cerebellopontine 
angle tumors . 
One of the most important components of the 
evaluation is the dizziness simulation battery. This 
battery exposes the patient to a number of situations 
that commonly trigger dizziness in an attempt to 
simulate the patient's own symptom. These maneu-
vers include: blood pressure determinations lying and 
standing, a standard Yalsalva maneuver for 15 sec-
onds, head turning with eyes open or closed, a sudden 
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turn when walking, hyperventilation for three min-
utes, and the Nylen-B<1rany test. 8 The latter maneu-
ver is a test for positional vertigo. The patient is 
abruptly moved from a seated to a supine position 
with the head hanging 45° backwards, and turned to 
one side and then the other. The patient is observed 
for vertigo and nystagmus , noting the onset, dura-
tion, and direction of nystagmus. 
Another simple technique which can be per-
formed in the office setting is the caloric test. Not 
only can vestibular function be assessed by this pro-
cedure but also the patient can compare the sensation 
produced with his own symptoms. One must first 
make certain that the ear canals are free of debris and 
that the drums are intact. If available, the use of 
15-20( +) lenses or Frenzel glasses will inhibit visual 
fixation and magnify the eyes for better observation. 
With the patient rec um bent and the head elevated 
30°, 3 to 5 cc of ice water are slowly poured into the 
ear. The eyes should then be observed for nystagmus 
which should be horizontal with the quick com-
ponent to the opposite side. How well the two sides 
agree is most important. A unilateral absent or hy-
poactive response may be the product of Meniere's 
disease, vestibular neuronitis or acoustic neuroma. 
Perversion of nystagmus, such as absence of the 
quick component, horizontal nystagmus, or a pro-
longed hyperactive response point to brain stem in-
volvement. It should be emphasized, however, that 
one should not try to read too much into the findings 
obtained by the caloric testing. 
Routine laboratory studies in the dizzy patient 
should include: a complete blood count, sedimenta-
tion rate, Fasting Blood Sugar (FBS), blood urea 
nitrogen (BUN), thyroid function studies, electrocar-
diogram, and skull x-rays with views of the internal 
auditory canals.8•9 
A more extensive evaluation is often needed. 
Patients with objective otologic abnormalities includ-
ing hearing loss should receive prompt referral to an 
otologist for audiologic testing and further diagnostic 
studies. The presence of abnormalities on neurologic 
examination or the history of ataxia , headaches, dis-
turbance of consciousness, or visual disturbance 
would necessitate neurologic consultation. Even in 
those patients with transient symptoms or in whom a 
benign etiology has been demonstrated, careful fol-
low-up is advisable. 
Treatment. The treatment of the dizzy patient 
obviously depends on the underlying cause. Since a 
benign condition underlies the majority of dizziness 
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cases, an important aspect of therapy in these 
patients is reassurance. Patients with peripheral ver-
tigo should be informed about vestibular habit-
uation. In other words , the nervous system will ordi-
narily adapt to an imbalance between the two end 
organs and vertigo will ultimately cease. In addition, 
since visual fixation has an inhibitory effect upon 
vestibular symptoms, vertiginous patients should re-
sist the tendency to close their eyes and should fix a 
nearby object. 2 The prophylactic use of drugs for 
symptoms of dizziness has not been very grat-
ifying. Most of the information on treatment is 
largely anecdotal. Va.sodilators such as nicotinic acid 
and betahistine are often recommended; however, I 
am unaware of any data that clearly support their 
efficacy. Valium® may be beneficial since it appar-
ently exerts some selective sedative effect on the ves-
tibular nuclei. 10 
Mecli zine in doses of 25 mg three times a day is 
perhaps the most popular and effective medication in 
the treatment of recurrent or continuous vertiginous 
symptoms. Cohen and Delong" demonstrated in a 
double-blind crossover study that meclizine was sig-
nificantly more effective than a placebo in the treat-
ment of vertigo. There was, in addition, no difference' 
in the response of patients with disease of the per-
ipheral or central vestibular systems. 
The table is reprinted from Neurology ©1972 by The New York 
Times Media Company, inc. 
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Management of Transient Brain Ischemia 
CLARK H. MILLIKAN, M.D. 
Professor of Neurology, Mayo Medical School, University of Minnesota , Minneapolis, Minnesota, and Director, 
Mayo Cerebrovascular Clinical Research Center, Rochester, Minnesota 
Cerebrovascular disease is an exciting subject, so 
complex that we could devote 30 minutes to a dis-
cussion of aspirin, dipyridamole, and sulfinpyra-
zone and their potential actions in the prevention of 
thromboembolic events. A Classification and Outline 
of Cerebrovascular Disease II , published in the Sep-
tem her-October 1975 issue of Stroke, depicts this 
complexity. The portion labeled "outline" describes 
some of the things summarized in this paper. 
The first part of the Classification is labeled 
"Clinical Stage"; it is where we make contact with 
mosi patients, including even those with asymptom-
atic bruit. The "Clinical Stage" is subdivided into 
"Transient lschemic Attacks," "Progressing Stroke," 
and "Completed Stroke." TIA is the abbreviation for 
transient focal cerebral ischemic attacks. It has be-
come popular. in the United Kingdom to refer to 
syncope as a TIA; elsewhere in the world, however, 
the word "focal" must be included in the term tran-
sient cerebral ischeniic attack; thus syncope is not 
listed urider "Transient lschemic Attacks." TI As are 
important because they are warnings of a serious or 
progressing or devastating stroke to come . They have 
certain significant characteristics: the onset is rapid 
(defined as no symptoms to maximal symptoms in 
less than two minutes) ; the duration commonly is 2 
to 30 minutes. In an attempt to establish a standard, 
we state in the Stroke dassification that a TIA can 
last as long as 24 hours . Seldom ; however, does a TIA 
last 24 hours ; most of us believe that someone who 
has a focal cerebrovascular event which lasts 20 
hours probably has a small infarct. An attack which 
Correspondence and reprint requests to Dr. Clark H. Milli-
kan , Professor of Neurology , University of Utah School of Medi-
cine, Salt Lake City, Utah 84112. 
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lasts two to five or ten minutes, as in amaurosis 
fugax , has not in that instance produced retinal is-
chemia to the point of retinal infarction. The same 
theory applies to the brain; an attack of short dura-
tion does not produce cerebral infarction . The resolu-
tion or disappearance of each episode is swift; the 
frequency of attacks is variable. Significantly, the 
diagnosis is almost always made on the basis of the 
history , particularly in office practice. Over 25 years I 
have witnessed only a few attacks. Frequently I am 
asked, "Did you really complete the study and prove 
the diagnosis by doing an arteriogram?" An arteri-
ogram will not reveal whether a patient has had a 
TIA or not; it will only display detail concerning the 
morphology of the vessels. Anatomically, TIAs are 
subdivided into two categories; carotid and vertebro-
basilar. With the development of surgical reconstruc-
tion for lesions in the carotid system, there is every 
reason for making the clinical distinction between 
these two symptoms. 
The typical history for a TIA in the carotid [arterial] 
system is ... : 
1. Motor defect (weakness, paralysis, poor use, or 
clumsiness of one extremity or of both extremities on the 
same side). 
2. Sensory defect (numbness including loss of sen-
sat ion or paresthesias involving one or both exremities 
on the same side). 
3. Aphasia (speech and/or language disturbance 
which may be only a minor defect or may be global and 
may or may not include difficulty in reading , writing, or 
performing calculations). 
4. Loss of vision in one eye or in part of one eye 
when vision in both eyes was intact (amaurosis fugax). 
5. Homonymous hemianopia. 
6. Combinations of the above. 
These clinical phenomena generally represent a de-
crease or absence of function. When there is a sensory 
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event, it is commonly described as coming on all at once, 
that is , without a march. 
The typical history for a TIA in the vertebrobasilar 
arterial system is . . 
I. Motor defect (weakness, clumsiness, or paralysis 
of any combination of extremities up to quadriplegia, 
sometimes changing from one side to another in differ-
ent attacks). 
2. Sensory defect (numbness, including loss of sen-
sation or paresthesias in any combination of extremities 
including all four or involving both sides of the face or 
mouth. This is frequently bilateral trouble or the distribu-
tion may change from side to side in different attacks). 
3. Loss of vision, complete or partial in both ho-
monymous fields (bilateral homonymous hemianopia). 
4. Homonymoµs hemianopia. 
5. Ataxia, imbalance, unsteadiness, or dysequilibrium 
not associated wit)l vertigo. 
6. Either vertigo (with or without nausea and vomit-
ing), diplopia, dysphagia , or dysarthria is not to be con-
sidered as a TIA when any of these symptoms occurs 
alone, but in combination with one another or with any 
of the above (numbers I, 2, 3 and 4) the attacks should be 
considered a TIA. 
7. Combinations of the above. 
These clinical phenomena generally represent a de-
crease or absence of function. At times, the motor, sen-
sory , or visual defect constituting the content of a verte-
brobasilar attack will be unilateral. It becomes difficult 
in such instances to make a distinction between whether 
the locus of ischemia is in the carotid arterial system or in 
the vertebrobasilar arterial system . In the list above, 
"drop attacks" is omitted. Fainting (syncope) is fre-
quently confused with a " drop attack ," so the latter 
should be included in the vertebrobasilar profile only 
when the patient's description of the "drop attack" is 
abso lutely clear. The variety of manifestations included 
in the vertebrobasilar profile makes the potential pat-
tern of symptoms considerably more variable and com-
plex than that in the carotid system. 
The diagnosis of TIA rests on the history of the at-
tacks; the skill with which the history is taken and the 
interpretation of the history , except for those relatively 
few instances where the physician is with the patient at 
the time of the attack. The criteria for making the diag-
nosis will vary depending on whether an individual 
physician is working with an individual patient or 
whether the purpose is the screening of a population for 
TIAs. A problem is created , as in much of medical diag-
nosis , because of the relative weight or significance of 
some historical phoriomena compared to other phenom-
ena. The symptom "numbness" (mentioned above) is 
an example. If the question is, "Have you ever had a 
numb hand9 , " the answer from most adults will be "yes." 
This question is almost completely non-selective (non-
diagnostic) and must be followed by a series of questions 
to establish the meaning and significance of the "numb-
ness. " In contrast , another phenomenon, when present , 
is simple and relatively much more significant than 
"numbness;" i.e., "Have you ever had painless blindness 
in one eye which came on very quickly (seconds) and 
lasted only a few minutes (5 to 20)?" is a question 
which , if answered "yes," is reasonably specific. Another 
similar but less specific question is " Have you ever had 
the sudden onset of a 5 to 20-minute duration attack of 
severe weakness of one side of the body (arm and leg)?" 
Another is "Have you ever suddenly lost the ability to 
speak (5 to 20 minutes' duration) or to understand the 
speech of others?" These questions illustrate the impor-
tance of understanding that different questions may have 
relatively different cqmplexity and importance. 
The matter of relative significance of different sym-
toms is important in the vertebrobasilar system as it is in 
the carotid system. For instance, if one asks the question , 
"Have you ever had any dizziness" ," almost all adults 
will answer "yes." This question is almost completely 
non-selective (non-diagnostic) and if answered affirma-
tively must be followed by a series of direct and branch-
ing questions to e?tablish the meaning and signific;mce 
of the original phenomenon-"dizziness." A diagnosis of 
a TIA in the vert~brobasilar system should not be made 
on the basis of a history of a few minµtes of vertigo as the 
only symptom. This is emphasized since vertigo is the 
most common symptom in the vertebrobasilar system ; 
however, a diagnosis of vertebrobasilar TIA is made only 
when there is concurrently with vertigo (dizziness) an ad-
ditional symptom or symptoms. 
In some instances, patients with carotid system 
TIAs may have physical signs of appropriate arterial 
disease. These include diminished pulsation in the carotid 
artery, a bruit over the carotid artery or eye, emboli in 
the retinal vessels, or other signs of ischemic retinopathy 
and relative hypotension in the retinal artery as measured 
with the ophthalmodynamometer. These are only signs 
of arterial disease and may be present in the absence of 
a history of TIAs. In certain instances , bruits signifying 
compromise of flow in the innominate artery, either 
subclavian artery, or at the origin of ei ther vertebral 
artery may be present ; however, the a bsence or presence 
of such sounds does not weigh heavily in the diagnosis of 
vertebrobasilar TIA since it is again emphasized that 
the diagnosis is dependent upon the history of the at-
tack , not upqn morphological evidence of change in 
patterns of blood flow . 
Certain symptoms may appear in a TIA in either 
arterial system . The most important of these are: 
I. Dysarthri~ , if it occurs alone, and 
2. Homonymous hemianopia , if it occurs alone. 
The occurrence of certain symptoms in solitary 
fashion constitutes an attack which is an "uncertain 
TIA. " An attack which consists solely of each of the fol-
lowing symptoms should be categorized as an uncertain 
TIA: 
I . Vertigo a lone 
2. Dysarthria alone 
3. Dysphagia alone 
4. Diplopia alone 
For the sake Qf clarity, the following symptoms, 
transient or prolonged, are not to be included as TIA: 
I. Unconsciousness including syncope 
2. Tonic and/ or clonic activity 
3. March of a sensory defect 
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4. Vertigo alone 
5. Dysphagia alone 
6. Dysarthria alone 
7. Incontinence of bowel or bladder 
8. Dizziness or wooziness a lone 
9. Loss of visio n associated wi th alteration of con-
sciousness 
IO. Focal symptoms associated with migraine 
11. Scintillating scotomata 
12. Confusion alone 
13. Amnesia alone 
The differential diagnosis of TI As includes "hemi-
plegic" migraine, focal convulsive events (often due to 
neoplasm and producing either sensory or motor 
phenomena), Meniere' s disorder, sensory phenomena 
associated with hyperventilation, and finally some un-
known mechanism. The differentiation of "hemiplegic" 
migraine is a semantic and practical problem. In those in-
stances where the aura of migraine is associated with a 
definitely focal neurological event, the latter may well 
be the result of transient focal cerebral ischemia but the 
implications are different than the usual TIA. To es-
tablish a diagnosis of the migraine association, there 
is ordi narily a positive family history, characteristic uni-
lateral headache with nausea and sometimes vomiting, 
and onset of the a ttacks several decades ahe~d of the age 
at which T!As commonly begin. Very careful history-
taking ordinarily delineates the transient focal events 
associated with brain neoplasm from T!As and this is 
also true of the other items in the differential diagnosis.' 
It is necessary to understand the pathogenesis of 
the attacks to treat them properly. Strokes occur in 
people who have atherosclerosis; common sites are in 
the cervical arteries and in the circle of Willis and its 
main branches. Strokes do not occur in patients free 
of atherosclerosis unless there is a distal occlusion by 
an embolus from the heart or other site. Cerebral 
infarcts are statistically associated with ather()-
sclerosis. How does a static atherosclerotic lesion 
in the neck produce the sudden onset, in a matter of 
seconds, of a hemiparesis which lasts for five minutes 
and disappears leaving the person normal? How of-
ten does cerebral atherosclerosis occur without caus-
ing symptoms? In 100 consecutive autopsies of 
patients 50 years of age or older, the arch of the 
aorta, all cervical vessels, vessels at the base of the 
brain , and the brain were studied. Under the term 
"stenosis," only a lumen narrowed 50% or more was 
counted. There were 77 cervical stenoses in 28 
patients. Of these 28 people, 18 had never had any 
symptoms of nervous system trouble of any kind . 
There were 15 cervical occlusions in 12 people. Six of 
these 12 had never had any symptoms of nervous 
system trouble. There were 40 people ( 40%) of 
the I 00 who had cervical atherosclerosis, not count-
ing intracranial lesions . Sixty percent of these pa-
tients were without any symptoms of nervous sys-
tem trouble. This same observation has been made 
concerning coronary atherosclerosis. Many people 
with coronary atherosclerosis have neither angina 
nor a myocardial infarction . It is apparent that some 
factor, in addition to atherosclerosis, has to be present 
to produce the sudden onset and short duration of 
the attacks . In 1955, I postulated that atherosclero-
sis plus one or more of the following could cause 
an attack: tra,nsient systemic hypotension, poly-
cythemia, kinking or external compression, shunting, 
transient hypoglycemia, vasospasm, severe anemia, 
thrombosis or embolism or both. The transient sys-
temic hypotension theory was in vogue over a decade 
ago. The notion was that if there were distal stenosis 
of an artery and the perfusion pressure dropped , 
there would be a disproportionate decrease in per-
fusion distal to the stenosis, thereby causing ischemia 
for the duration of that decreased perfusion pressure, 
and ischemia in the territory supplied by that vessel. 
The physician should search for cardiac causes of 
transient systemic hypotension even though this is an 
uncommon cause of TIA . At the Mayo Clinic, only 
1.4% of 290 consecutive patients being implanted 
with cardiac pacemakers had had focal transient neu-
rological phenomena. In most instances there were 
episodes of diffuse cerebral ischemia (syncope). Poly-
cythemia is found in I% or 2% of our TIA patients, 
whether vertebro-basilar or carotid. Polycythemia 
should be appropriately studied and treated. Reversal 
of flow in a vertebral artery because of occlusion or 
stenosis of a subclavian artery has been called "sub-
clavian steal." It can be diagnosed in the office as 
there is a decrease in brachial blood pressure on the 
side involved, a radial pulse lag, and a decrease in the 
palpable pulse pressure on that side. The symptom 
complex associated with this, certainly in our institu-
tion, has never been defined and operations for this 
defect are seldom performed. 
The items of greatest importance in the patho-
genesis of TIA appear to be thrombosis and embo-
lism . Cholesterol and fibrin-platelet emboli have been 
observed in the retina; streamlining of flow explains 
the similarities between the neurological content of a 
patient's attacks while fragmentation of emboli or 
lysis of thrombosis is a plausible explanation for the 
short duration of episodes. The appearance of choles-
terol emboli in the retina means that there is an 
ulcerated carotid lesion on that side. 
The natural hi story of TIA has received consid-
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erable study. Are TIAs warning events? Twelve re-
ports are summarized in the following table (Table 
I ). 
The one study with a result different from the 
others is Marshall's .9 A few months later, Marshall13 
published an entirely different result ; 43% of TIA 
patients had cerebral infarction when followed for 
60 months. In Marshall's first report it appears that 
many of the patients had a complaint of occasional 
dizziness and were not having focal cerebral transient 
ischemic attacks. In the study by Pearce et al,5 the 
duration of follow-up was only 10.6 months which 
is too short a time to discover the true natural history 
of TIA. 
One is often asked about the indications for cra-
nial arteriography. These are: 
I. Differential diagnosis of the brain pathology. 
Even with careful attention to all the items listed 
under history, general examination , neurological ex-
amination, neurovascular examination, and addi-
tional tests, there still remain about 5% of patients 
whose diagnosis is uncertain. Computerized tomog-
raphy (EMI, ACTA , DELTA scanners, and others) 
is revolutionizing the differential diagnosis of in-
tracranial lesions. In a few instances , cervical-cere-
bral angiography is the best method for distin-
guishing between vascular occlusive disease, an 
intracerebral expanding mass such as hemorrhage, 
abscess or brain tumor, cerebral infarction, and sub-
dural hematoma, as well as demonstrating aneurysms 
and arteriovenous malformations. 
2. Transient focal ischemic attacks, particu larly 
in the carotid system. Cervical-cerebral angiography 
should be performed if one or more of these condi-
tions is evident: amaurosis fugax, bruit over the be-
ginning of the internal carotid artery, retinal emboli, 
unilateral decrease in retinal artery pressure, or is-
chemic retinopathy . If none of these is present, the 
likelihood of finding a lesion accessib le to the surgeon 
is small. 
3. Selected instances of vertebra-basilar TIAs. 
It may be difficult to make a clinical distinction be-
tween the carotid and the vertebra-basilar system. If 
the TIAs are characteristic of those coming from the 
vertebra-basilar system, there is litt le need for exten-
sive angiography . 
4 . Early progressing stroke or frequent TIAs in 
the carotid system with evidence of amaurosis, an 
appropriate bruit, retinal emboli, or other conditions. 
5. Many patients with subarachnoid hemor-
rhage and some patients with intracerebral hemor-
rhage. 
A less certain indication for cranial arteri-
ography is a loud, long systolic or systolic-diastolic 
internal carotid artery bruit in patients scheduled for 
major general surgery. If there is prolonged hypoten-
sion or very severe blood loss, the carotid stenosis 
may decrease blood supply to a focal region of the 
brain to a critical level of ischemia. Recent observa-
tions suggest that such patients do not have an in-
creased risk of stroke; therefore, arteriography is not 
necessary. 
Table I 
STUDY 
Sieker! et al' 
Cooperative' 
Fisher' 
Pearce et a I' 
Baker et al' 
Baker et al' 
Friedman et al' 
Marshall' 
Ziegler and Hassanein" 
Goldner* et al" 
Whisnant et al 12 
Marshall 13 
Twelve Reports Summarizing Natural History of TIAs as Warning Events 
NU MBE R OF FOLLOW- UP 
PATIENTS (Mos.) 
160 60 
20 20 
23 
20 10.6 
30 40.6 
79 41 
23 27.4 
61 45 
135 36 
140 180 av •1 
Ill av? 
198 60 
158 60 
NORMAL 
83 (52%) 
11 (55%) 
54 (89%) 
CEREBRAL INFA RCT 
TOTAL 
51 (32%) 
5 (25%) 
8(34%) 
2(10%) 
7 (23%) 
17 (22%) 
8 (35%) 
1 (2%) 
22(16%) 
43 (38%) 
62 (32%) 
68 (43%) 
LETH AL 
18(11 %) 
1 (5%) 
0 
0 
I (2%) 
5 (3.7%) 
27 (24%) 
CER EBRA!. 
HEMORRHAGE 
7(4%) 
0 
0 
I (2%) SAH 
*Goldner, Whisnant and Taylor reported concerning 140 TIA patients followed for 15 years. The table gives occurrence of stroke 
in 111 patients. 
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Recalling the thrombosis-embolism mechanism , 
it is apparent that there are several ways to treat 
TIAs; one of these is the administration of an oral 
anticoagulant. Table 2 shows the data in six reports 
in which a direct attempt has been made to compare 
untreated patients suffering from transient ischemic 
attacks with those receiving anticoagulant drugs. 
Anticoagulants should not be used if: 1) the 
physician is unfamiliar with the drugs, 2) the patient 
is not fully cooperative, or 3) laboratory results are of 
uncertain quality. The actual number of patients in 
five of the studies in Table 2 is so small as to make 
comparison between the treated and untreated 
groups invalid. Nevertheless, the percentage of in-
dividuals with cerebral infarction was similar in 
all of the treated groups of each study. The effective-
ness of concurrent treatment of arterial hypertension, 
in decreasing the frequency of intracerebral hemor-
rhage, cannot be assessed in these studies; it seems 
reason a ble that the danger may be less now that 
antihypertensive therapy is better developed. It is 
apparent that anticoagulant therapy decreases the 
risk of cerebral infarction in patients with transient 
ischemic attacks. However, other types of treatment 
should be considered including thromboendarter-
ectomy and the administration of antiplatelet ag-
glutinating agents. 
Although thousands of operations on the carotid 
artery have been performed since the report by East-
cott, Pickering and Rob 14 in 1954, knowledge con-
cerning the effects of surgery to prevent subsequent 
cerebra l infarction in patients with TIA is still lim-
ited . In the Joint Study of Extracranial Arteria l Oc-
clusion V,15 the collaborating investigators reported 
that 316 patients had transient ischemic attacks; 169 
received surgical treatment and 14 7 received medical 
treatment. The follow-up period averaged 42 months. 
In the surgically treated group, 15% of the patients 
suffered cerebral in farction (including postoperative 
complications) while 14% of the medically trea ted 
subjects had cerebral infarction. The best results were 
noted in a subgroup of 94 patients having transient 
ischemic attacks and unilateral carotid stenosis; 45 
underwent surgery and 49 were treated medically. Six 
percent of the surgica lly treated patients had cerebral 
infarction during the total course of the study com-
pared with 12% of the medically treated group. Ba uer 
et a l,16 a lso reporting for the Joint Study of Extra-
cranial Arterial Occlusion, noticed statistically signif-
icant differences in the cumulative survival rates at 42 
months and reported that: 
( I) surgical treatment appeared more beneficial for 
unilateral carot id stenosis in patients with transient 
ischemic attacks or a mild to moderate neurological 
TABLE 2 
Six Studies Comparing Untreated TIA Patients with Those Receiving Anticoagulant Therapy 
NUMBER OF 
STUDY PATI ENTS 
Siekert el al' 
Control 160 
Treated 175 
Cooperative Study' 
Control 20 
Treated 24 
Fisher' 
Control 23 
Treated 29 
Pearce et a l' 
Control 20 
Treated 17 
Baker et al' 
Control 30 
Treated 30 
Friedman et al' 
Control 23 
Treated 2 1 
FOLLOW-UP 
(Mos.) 
60 
60 
20 
18 
30 
10.6 
II.I 
40.6 
37.9 
27.4 
27.4 
NORMAL 
83 (52%) 
131 (75%) 
11 (55%) 
7 (41%) 
*Three treated patients randomly chosen had CY A after A/ C stopped. 
1 One cerebral hemorrhage in treated group but while off anticoagulant. 
CEREBRAL INFA RCT 
TOTAL LETHAL 
51 (32%) 18( 11 %) 
7(4%) 3(2%) 
5 (25%) I (5%) 
I (4%) 0 
8(34%) 0 
I (3%) 0 
2( 10%) 
I (5%) 
7* (23%) 
2 
8• 0 
0 0 
' One patient had been on A/ C, but A/ C was discontinued before the cerebral infarction. 
CE REBRAi. 
H EMO RRllAGF 
7 (4%) 
13 (7%) 
0 
2 (8%) 
0 
0 
0' 
I (4%) SAH 
0 
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deficit, (2) nonsurgical treatment produced better results 
for unilateral carotid stenosis in patients with a moderate 
to severe neurological deficit, (3) nonsurgical treatment 
appeared more beneficial for combined unilateral 
carot id a rtery stenosis and contra latera l carotid artery 
occlusion o f patien ts who had a moderate to severe 
neurological deficit, and (4) nonsurgical treatment ap-
peared more beneficial for patients with completed 
strokes who had a marked and persistent neurological 
deficit. 
It is apparent from the ma ny reports in the liter-
a ture that physicians clinically active in the cerebro-
vascular field are modera tely to g reatly enthusiastic 
about surgica l treatment for carotid system TIA 
when an appropriate carotid lesion is di scovered. U n-
fortunately, no long-term follow-up of a precisely 
studied group o f surgically treated carotid TIA 
patients is available, but it seems likely that results 
have improved since the report by the Joint Study of 
Extracrania l A rteri a l Occlusion . 
In the last decade, aspirin, dipy ridam ole (Per-
santine®) and sul fi npyrazo ne (Anturane®) have been 
investigated in the la boratory and in some huma n 
clinical settings because of their effect on blood plate-
let aggregability or adhesiveness or both. A direct 
relat ionship between these characteristics of platelets 
and the pathogenesis of transient ischemic attacks 
has not yet been firmly established . Dyken et al17 de-
scribed 26 patients, in a retrospective study, of whom 
15 were treated with aspirin (300 mg b.i .d .) and 11 
were not. No difference was noted in the incidence of 
cerebral infarction or death in the two groups, but 
on ly two ( 13%) of those receiving aspirin had an ad-
ditional TIA while nine (82%) of those receiving no 
aspirin had subsequent TIA . The author stressed that 
this study did not prove the effecti veness of aspirin , 
but that it pointed to the need for a prospective in-
vestigation of the subject. 
Two cooperative studies of platelet aggregating 
agents' effect o n transient ischemic attacks are under-
way, one in Canada and o ne in the United States. 
Formal comprehensive reports from these studies a re 
not yet available. A tthe Tenth Princeton Conference 
on Cerebral Vascular Disease in 1976, Fields18 gave a 
brief overview of some of the experience in the 
United States Cooperati ve Study of aspirin for the 
treatment of transient foca l cerebra l ischemic attacks. 
He reported that in patients hav ing one attack, there 
was no difference between treated and untreated 
patients, but that in patients having multiple TIAs, 
those receiving aspirin appeared to have a better "re-
sult. " This Cooperative Study has been discontinued. 
Barnett'" (Canadian Cooperative Study) was asked 
about the results of his investigation which involved 
comparisons between several treatments (aspirin, sul-
finpyrazone, and other drugs). He commented that 
the stat istics to date had been ca refully reviewed and 
that the results appeared to be inconclusive. There 
was no reason to stop the investigatio n and every 
reaso n to continue it. At this time, the pressing ques-
tions concerning the effectiveness of these agents re-
ma in unanswered . 
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Recent Techniques in Cerebrospinal Fluid 
Examination 
VINCENT P. CALABRESE, M .D . 
Assistant Professor of Neurology, Medical College of Virginia, Health 
Sciences Division of Virginia Commonwealth University, Richmond, Virginia 
The existence of the cerebrospinal fluid (CSF) 
has been known since ancient times, but it was Co-
tugno who first described it in some detail in 1764. 1 
Quoting from his treatise, "In these experiments 
which I made on the bodies of nearly twenty adults, 
and which I repeated at different times , I could draw 
off freely from the hollow of the spine, four, or even 
sometimes five ounces of water: I commonly found it 
very clear in such su bjects, though it sometimes in-
clined a little to a yellow color: but in fetus' strangled 
in difficult labor, little as it was, I observed it to be 
always red and opaque."2 He also felt that the CSF 
was secreted by the arterial system, circulated in the 
subarachnoid space and was reabsorbed by the 
venous system.2 Matters remained in that state until 
1891 when Quincke described a refinement in lumbar 
puncture using a needle with a pointed stilette in it. 3 
The first extensive treatise on CSF composition was 
written by Mestrezat in 1912.1 Since then there has 
been very slow progress in the evaluation and inter-
pretation of CSF even though there have been tre-
mendous strides in the evaluation of other body 
ft uids, particularly blood . 
One of the reasons for this is a fear of lumbar 
puncture, a fear which is usually unwarranted. Un-
fortunately, this attitude permeates the medical pro-
fession almost as much as it does the lay public. 
Tests such as cell counts, glucose, protein, and 
semiquantitative tests for globulins such as the col-
loidal gold test were products of the first part of this 
Correspondence and reprint requests to Dr. Vincent P. Cala-
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century. As new developments occurred in blood 
analysis these were applied to the CSF . These studies 
did not lead to any advances in the clinical chemistry 
of CSF, though they certainly had their place in 
furthering our understanding of brain chemistry and 
function . 
The biggest advance in clinical CSF chemistry in 
the past decade has been the emergence of an abbre-
viated CSF immunology. This followed the develop-
ment and refinement of agar electrophoresis and im-
m unoprecipitation techniques. 
The scope of this paper will include discussion of 
these advances and some promising studies of CSF 
enzymes in differential diagnosis as well as comment 
on a recurrent problem , that of the interpretation of 
bloody or xanthochromic CSF. 
Blood in the CSF. Probably one of the most 
frequently encountered problems is the bloody CSF. 
Is it a subarachnoid hemorrhage or is it a traumatic 
tap? 
One of the best tests and the one most commonly 
used is to do a cell count in the first tube and another 
in a subsequent tube, usually the third . This should 
be done even if the fluid looks grossly clear since 
about 500 cells must be present before the fluid be-
comes hazy .4 •5 A significant change in the red blood 
cell (RBC) count of the fluid indicates a traumatic tap 
since the blood from a subarachnoid hemorrhage 
should be homogeneous by the time it reaches the 
lumbar sac. I say a "change" in the RBC, not just a 
decrease, since a marked increase would also indicate 
a traumatic tap . One should also closely observe the 
fluid as it comes out of the needle . Gross blood can 
sometimes be seen streaming in the fluid. One may 
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also see nonhomogeneous mixing in the ft uid as it 
drops into the tube. In addition, a very bloody trau-
matic tap (greater than 200,000 RBC/ mm3 ) will clot 
on standing; this will not occur with subarachnoid 
bleeding. Microscopic examination of the red cells is 
of little value since crenation may occur with both 
subarachnoid bleeding and a traumatic tap. 
The next step if the fluid is bloody or colored 
should be to centrifuge the fluid and determine the 
color of the supernatant. One often hears the remark 
that the fluid was xanthochromic, yet the fluid was 
not centrifuged. Xanthochromia should refer to a 
yellow color of the supernatant and should never be 
used in reference to unspun CSF. This coloration is 
usually due to either oxyhemoglobin, methemoglobin, 
or bilirubin. Very rarely it may be due to other pig-
ments such as carotene.6 
The sequence of events appears to be: hemoglo-
bin is released from the red cells in the subarachnoid 
space. This appears as oxyhemoglobin which in low 
concentrations has an orange-red appearance. De-
pending on the amount of bleeding, one begins to see 
a change in the coloration of the fluid to yellow 
within a few hours to a day. This is due to the heme 
being metabolized to bilirubin. In the case of a sub-
dural or an intercerebral hematoma the fluid may 
take on a brownish-yellow appearance due to the 
presence of methemoglobin. 
The supernatant fluid in a traumatic tap can give 
one of two results. It is usually clear and colorless 
since the red cells have not had time to break down. If 
the RBC count is high, however, (> 12,000/ mm3 ), 
some of the hemoglobin leaking out may be visible 
immediately.5 
True subarachnoid bleeding will give different 
results depending on the time elapsed following the 
bleed . One should keep in mind that it may take a 
half hour for blood to reach the lumbar sac from the 
cortex. The CSF may be indistinguishable from a 
traumatic tap very shortly after the hemorrhage. In 
his classic text on subarachnoid hemorrhage, Walton 
observed xanthochromia in 7% of patients within 2 to 
4 hours, but by 4 to 6 hours, 64% had it, and by 12 to 
24 hours, 100% had it. 7 
There have been periodic attempts at using spec-
trophotometry as an aid in evaluating CSF pigments. 
The three major pigments have rather characteristic 
absorption patterns. Kronholm and Lintrup did a 
study on 1,250 CSF samples and were able to develop 
a set of formulae for determining the concentrations 
of hemoglobin, methemoglobin, and bilirubin. Their 
results showed that they could distinguish between 
intercerebral hematomas, subdural hematomas, and 
subarachnoid hemorrhage (Table 1; Fig 1 ).8 
More recently, Kjellin and his group have ex-
panded on this theme of CSF spectroscopy .9·' 0 Be-
sides the disorders noted above, they have been able 
to correlate various CSF patterns with hemorrhagic 
infarctions, nonhemorrhagic infarctions, and emboli , 
as well as hem a tom as and subarachnoid hemorrhage. 
In the past they have had to rely on clinical and 
occasional autopsy conformation. When this was 
available there was good correlation (Table 2 ). 
I do not advocate that these procedures be used 
in place of others for evaluation of bloody CSF, but 
as adjuncts which may be invaluable in deciding if a 
!um bar puncture was traumatic or not. 
CSF Proteins and Immunoglobulins. There is con-
siderable evidence that under normal circumstances 
the proteins of the CSF are derived from the serum ." 
The most notable exception is the so-called (tau) 
protein seen in electrophoresis which is probably se-
rum transferrin which has lost two sialic acid residues 
(Fig 2). Normally, the CSF proteins are made up of 
albumin, (3 globulin and 'Y globulin in the fractions 
0.58, 0.20, and 0.10 respectively. These get into the 
CSF by secretion from brain tissue as well as from the 
choroid plexus. Efflux of protein is presumably 
through bulk flow , through the arachnoid granules. 
Increases in protein , especially albumin, can come 
from: 1) hemorrhage into the CSF, 2) breakdown in 
the blood-brain barrier, 3) elevated serum protein, 4) 
lesions of the choroid plexus or 5) blockage of CSF 
flow, for example, spinal block , and 6) an efflux of 
soluble proteins into the CSF with damage to brain 
tissue. 
CSF 'Y globulin or IgG also comes from the 
serum in normal persons. In conditions where there is 
Table I 
CSF Pigments in Xanthochromic CSF 
lnte rcerebral hematoma Bilirubin > Hemoglobin 
Methemoglobin > 25% total Hb 
Subdural Same as above, but metheme 
may be very high 
Subarachnoid Hemoglobin > Bilirub in 
Methemoglo bin < 25% 
Traumatic Same as subarachnoid though 
Bilirubin should be negligible 
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Fig I-Absorption pattern of CSF. A is from a patient who did not have active CNS disease. Bis from a patient who presented with a 
history of confusion and a bloody CSF. The absence of a hemoglobin peak indicates blood was from a traumatic tap, but bilirubin indicates 
an older subarachnoid hemorrhage. C is from a patient three weeks after an intercerebral hemorrhage. The hemoglobin peak is over 50% 
metheme. D is hemolyzed blood. 
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Table 2 
Spectrophotometric Evaluation of CSF in Vascular Disease 
Pattern (% of cases)* 
Hemorrhagic infarction 
Verified Disease 
Infarction 
Cerebral Hemorrhage 
Aneurysm 
Trauma (not subdural) 
Infarction 
71 
9 
or 
Hematoma 
24 
46 
8 
Mixed 
8 
8 
18 
Hemorrhage 
27 
83 
82 
*A small number could not be interpreted, so figures do not add up to !00%. 
an increased serum 'Y globulin or IgG, this will be 
reflected in the globulin composition of the CSF. In 
addition, if there is a breakdown in the blood-brain 
barrier, one may see an increase in the 'Y or lgG 
fraction simply because it makes up a higher propor-
tion of the total protein in serum than it does in CSF. 
There are times, though, when it appears that the 
increased immune globulins are coming from the 
brain itself. This was shown some years ago by Frick 
and Scheid-Seydel who used tagged lgG. 11 In mul-
tiple sclerosis (MS) patients they showed that a large 
portion of the lgG was coming from somewhere 
Serum 
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Fig 2-Agar gel electrophoresis of concentrated CSF and uncon-
centrated serum. Note presence of a prealbumin and a tau band in 
CSF which is not present in serum. Also note very broad gamma 
band. 
other than serum. At present it is thought that it is 
coming from immune competent cells situated in the 
periphery of MS plaques. 12 Other conditions which 
are felt to reflect central nervous system (CNS) lgG 
production with a raised CSF IgG are neurosyphilis 
and subacute sclerosing panencephalitis. Disorders 
such as meningitis or encephalitis may show in-
creased IgG either from a breakdown in the blood-
brain barrier or CNS production. 
In 1964, Lowenthal applied agar electrophoresis 
to CSF and was able to confirm this increase in im-
mune globulins (See Fig 2; Fig 3).13 Interestingly, con-
ditions which have CNS immune globulin production 
usually show discrete banding of the 'Y fraction while 
those conditions in which the immune globulins orig-
inate in serum show a diffuse 'Y band . The next ad-
vance after agar electrophoresis was the development 
of immunoprecipitation methods, either elec-
troimmunodiffusion or radial immunodiffusion 
where antibody to the immune globulins is added to 
the agar. The distance of the resultant precipitate 
from the origin is proportional to the immune globu-
lin concentration. The advantage over elec-
trophoresis is that only a few microliters of CSF are 
needed, and the subfractions of the immunoglobulins 
can be measured. The disadvantage is that only one 
protein fraction can be measured at a time. 
Interestingly, the results by the different meth-
ods are remarkably similar. 13 - 20 In MS some 75% 
to 85% of the patients show an abnormal 'Y or IgG 
level at some time in their disease. There is no re-
lationship, however, to the stage of the disease or to 
the prognosis. Its value is therefore purely diagnostic. 
Inflammatory diseases such as meningitis and en-
cephalitis show an increased level in some 35% to 
40%, the lowest level being in viral meningitis. Guil-
lain-Barre syndrome shows an increase in 30% to 
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Fig 3-Agar gel elect rophoresis of CSF from two patients wi th 
elevated gamma fraction. The first is a pat ient with acute lead 
encephalopathy. The diffuse gamma band is ind icative of a serum 
source whi le the multiple bands from the multiple sclerosis patient 
indicate a CNS source. 
50%. Agar electrophoresis shows that this is a serum 
pattern . In other diseases such as degenerative dis-
ease, tumors, and vascular disease, the percentage 
with increased 'Y or IgG levels is quite low, though in 
these conditions the literature does vary a great deal 
and probably reflects variations in the integrity of the 
blood-brain barrier (Table 3 ). 
CSF Enzymes. The measurement of CSF enzyme 
levels has no t yielded the kind of information which 
was hoped for. The ones measured most commonly, 
lactic dehydrogenase (LDH) and glu tamic-oxalacetic 
Table 3 
Conditions Giving Elevated CSF Gamma Globulin 
Systemic Conditions with Conditions with I 0 Increase 
Increased CSF Immune G lobulins in CSF Immune G Jobulins 
Ci rrhosis with T y globulin 
Myeloma 
Diseases with breakdown BBB 
Multiple Sclerosis 
CNS Lues 
SSPE 
Vascu litis.~----?Vascul i t i s* 
In fection----~I nfection * 
Sarcoidosis---~Sarcoidos is* 
* In these three it is uncertain if the origin of the gamma 
globulin is serum or CNS or both. 
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Fig 4-CSF LDH isoenzymes measured by aga r gel elec-
trophoresis. Normal LDH 2+ 3 = 0.40 and LDH I = 0.55. The 
LDH 2+ 3 curve follows the tota l LDH pattern whi le the LDH I 
actually showed a slight increase at two days when the absolute 
amount was calculated. 
transaminase (GOT), appea r to be elevated whenever 
there is significant disruption of brain tissues and do 
not seem to be specific for a given disease. The LDH 
is a lso increased when there is an increase in CSF 
polymorphonuclear cells. This relation to tissue de-
struction is shown by the results from a patient with 
recurrent strokes. Using LDH isoenzymes, it is of 
interest to note the transient shift to the more anae-
robic forms of LDH during the acute phase (Fig 4). 
CSF LDH has been noted to be elevated in 
meningitis of bacterial origin, but rarely in viral.21 - 23 
T his elevation has been used to try and differentiate 
partially treated bacterial from viral meningitis .24 For 
technical reasons the results were not really conclu-
sive, but it d id ind icate a differentiation could be 
made by an elevated level in bacterial d isease. 
More impressive was a study on CSF lactate 
before, during, and after treatment.25 Bacterial dis-
ease showed an elevated lactate level un til after full 
treatment while aseptic meningitis was the same as 
the controls. CSF pH showed the inverse pattern as 
wou ld be expected . 
While further studies wi ll be necessary to con-
firm these results, the outlook for a test to distinguish 
partially treated bacterial disease from a viral men-
ingitis looks promising. 
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Table I is adapted from Kronholm and Lintrup, Acta Psychiat 
Neural Scand (35:314-329, 1960). 
Table 2 is adapted from Kjellin and Soderstrom, J Neural Sci (23: 
359-369, 1974 ). 
REFERENCES 
I. DEJONG RN: The Neurologic Examination. New York, Harper 
& Row, 1970, chap 57. 
2. VIETS HR: Domenico Cotugno: His description of the cerebro-
spinal fluid. Bull Inst Hist Med 3:701-739, 1935. 
3. QuINCKE H: Die lumbalpunction des hydrocephalus. Berlin 
klin Wochenschr 28:929-933, 189 l. 
4. McMENEMY WH: The significance of subarachnoid bleeding. 
Proc Royal Soc Med 47:701-704, 1954. 
5. TOURTELLOTTE WW, SOMERS JF, PARKER JA, ET AL: A study 
on traumatic lumbar punctures. Neurology (Minneap) 8:129-
134, 1958. 
6. BARROWS LJ, HUNTER FT, BANKER BQ: The nature and clini-
cal significance of pigments in the cerebrospinal fluid. Brain 
78:59-80, 1955. 
7. WALTON J: Subarachnoid Hemorrhage. Edinburgh, E S Liv-
ingston, 1956, chap 7. 
8. KRONHOLM V, LINTRUP J: Spectrophotometric investigations 
of the cerebrospinal fluid in the near-ultraviolet region. Acta 
Psychiat Neurol Scand 35:314-329, 1960. 
9. KJELLIN KG, SODERSTROM CE: Diagnostic significance of 
CSF spectrophotometry in cerebrovascular diseases. J Neurol 
Sci 23:359-369, 1974. 
10. KJELLIN KG, SODERSTROM CE, CONQVIST S: Cerebrospinal 
fluid spectrometry and computerized transverse axial tomog-
raphy (EM! scanning) in cerebrovascular diseases. Eur Neural 
13:315-331, 1975. 
11. TOURTELLOTTE WW: On cerebrospinal fluid immunoglobulin-
G (IgG) quotients in multiple sclerosis and other diseases. J 
Neurol Sci 10:279-304, 1970. 
12. SIMPSON JF, TOURTELOTTE WW, KOKMEN E, ET AL: Fluores-
cent protein tracing in multiple sclerosis brain tissue. Arch 
Neurol 20:373-377, 1969. 
13. LOWENTHAL A: Agar gel electrophoresis in neurology. Elsevier, 
Amsterdam , 1964. 
14. SCHNECK SA, CLAMAN H: CSF immunoglobulins in multiple 
sclerosis and other neurologic diseases. Measurement by elec-
troimmunodiffusion. Arch Neurol 20:132-139, 1969. 
15. LATERRE E, CALLEWAERT A, HEREMANS JF, ET AL: Elec-
trophoretic morphology of gamma globulins in cerebrospinal 
fluid of multiple sclerosis and other diseases of the nervous 
system. Neurology (Minneap) 20:982-990, 1970. 
16. LINK H, MOLLER R: Immunoglobulins in multiple sclerosis 
and infections of the nervous system. Arch Neurol 25:326-344, 
197 l. 
17. TOURTELLOTTE WW, TAVOLATO B, PARKER JA, ET AL: Cere-
brospinal fluid electroimmunodiffusion. Arch Neural 25:345-
350, 197 l. 
18. FISCHER-WILLIAMS M, ROBERTS RC: Cerebrospinal fluid pro-
teins and serum immunoglobulins. Arch Neurol 25:526-534, 
1971. 
19. BERNER JJ, C!EMINS YA, SCHROEDER EF JR: Radial immuno-
diffusion of spinal fluid. Arn JC/in Path 58:145-152, 1972. 
20. OLSSON JE, LINK H: Immunoglobulin abnormalities in 
multiple sclerosis. Arch Neural 28:392-399, 1973. 
21. LENDING M, SLOBODY LB, MESTERN J: Cerebrospinal fluid 
glutamic oxalacetic transaminase and lactic dehydrogenase 
activities in children with neurologic disorders. J Ped 
65:415-421, 1964. 
22. NECHES W, PLATT M: Cerebrospinal fluid LOH in 287 chil-
dren, including 53 cases of meningitis of bacterial a nd non-
bacterial etiology. Pedia1rics 41: I 097- 1103, 1968. 
23. BEATY HN, OPPENHEIMER S: Cerebrospinal-fluid lactic dehy-
drogenase and its isoenzymes in infections of the central ner-
vous system. N Engl J Med 279:1197-1202, 1968. 
24. FELDMAN WE: Cerebrospinal fluid lactic acid dehydrogenase 
activity. Arn J Dis Child 129:77-80, 1975. 
25. BLAND RD, LISTER RC, RIES JP: Cerebrospinal fluid lactic 
acid level and pH in meningitis. Arn J Dis Child 128: 151-156, 
1974. 

A service to medical education from A. H. Robins: 
Excerpted from Volume 2 
offheG.I. 
Sen es 
on physical examination 
of the abdomen 
Normally palpable organs: 
the edge of the liver descending, 
on inspiration, below the costal 
margin (A) ; the lower pole of the 
right kidney (BJ ; the abdominal 
aorta (CJ ; the descending colon 
and the sigmoid (DJ ; the ascend-
ing colon (EJ ; and occasionally 
the bladder (though rising of 
this organ beyond the pubis 
does not necessarily indicate 
disease) 
Impossible to ou tline, unless 
diseased, distended or enlarged 
the gallbladder, pancreas , 
stomach, small intestine, trans-
verse colon and spleen 
The A. H. Robins G.I. Series consists of six book-
lets , designed to provide a quick . yet comprehen-
sive review of basic procedures and practices 1n 
GI . medicine - with particular emphasis on the 
physical examination as performed in the office or 
at bedside If you have teac hing responsibilities . 
limited quantities are available Part 1 - Inspection . -.... 
Part 2 - Palpation . Part 3-Percussion. Part 4 - Auscultation. Part 5 -
Abdominal Pain and Part 6 - Dlfferenf/al Diagnosis of Abdo minal 
Disorders . Write to The Medical Department , AH . Robins Company, 
1407 Cummings Drive. Richmond . Virginia 23220 
A service to medical education from A. H. Robins: 
Excerpted from Volume 2 
oftheG.I. 
Sen es 
on physical examination 
of the abdomen 
Normally palpable organs: 
the edge of the liver descending, 
on inspiration, below the costal 
margin (A); the lower pole of the 
right kidney (B); the abdominal 
aorta (CJ; the descending colon 
and the sigmoid (D); the ascend-
ing colon CEJ; and occasionally 
the bladder (though rising of 
this organ beyond the pubis 
does not necessarily indicate 
disease) 
Impossible to outline, unless 
diseased, distended or enlarged 
the gallbladder, pancreas, 
stomach, small intestine, trans-
verse colon and spleen 
The A . H. Robins GI. Series consists of six book-
lets, designed to provide a qu ick , yet comprehen-
sive review of basic procedures and practices in 
GI. medic1ne - w1th particular emphasis on the 
physical examination as performed in the office or 
a t bedside If you have teaching responsibilities . 
limited quantities are available: Part 1 - /nspect1on, 
Part 2-Palpation, Part 3 - Percussion, Part 4 - Auscultation. Part 5 -
Abdominal Pain and Part 6 - D ifferent1al Diagnosis of Abdominal 
Disorders. Write to The Medical Department, AH . Robins Company, 
1407 Cummings Drive. Richmond . V irginia 23220. 
each tablet, 
capsule or 5 cc. 
teaspoonful 
of elixir 
(23% alcohol) 
hyoscyamine sulfate 0 .1037 mg. 
atropine sulfate 0.0194 mg. 
hyoscine hydrobromide 0 .0065 mg. 
each 
Donnatal 
No.2 
0.1037 mg. 
0.0194mg. 
0 .0065mg. 
Phenobarbital (14 gr.) 16.2 mg, 
(warning: may be habit forming) 
( l-2 gr.) 32.4 mg. 
each 
Extentab 
0.3111 mg. 
0.0582mg 
0.0195mg. 
(%gr.) 48.6 mg. 
• Brief summary. Adverse Reactions: Blurring of vision, dry mouth, difficult urination, and flushing or dryness of the skin may occur 
on higher dosage levels, rarely on usual dosage. Contraindica-
tions: Glaucoma; renal or hepatic disease; obstructive uropathy 
(for example, bladder neck obstructiofl due to prostatic hyper-
trophy); or hypersensitivity to any of the ingredients 
A·H·ROBI NS AH. Robins Company, Richmond. Virginia 23220 
each tablet, 
capsule or 5 cc. 
teaspoonful 
of elixir 
( 23%alcohol) 
hyoscyamine sulfate 0.1037 mg. 
atropine sulfate 0.0194 mg 
hyoscine hydrobromide 0.0065 mg. 
each 
Donnatal 
No.2 
0.1037 mg. 
0.0194 mg. 
0 .0065mg. 
Phenobarbital ( Jl.i gr.) 16.2 mg. 
(warning may be habit forming) 
( V2 gr.) 32.4 mg 
each 
Extentab 
o.311 1 mg. 
0.0582 mg. 
00195mg. 
(:V. gr.) 48 6 mg. 
• Brief summary. Adverse Reactions: Blurring of vision , dry mouth, 
difficult urination, and flushing or dryness of the skin may occur 
on higher dosage levels, rarely on usual dosage. Contraindica-
tions: Glaucoma; renal or hepatic disease; obstructive uropathy 
(tor example, bladder neck obstructioA due to prostatic hyper-
trophy) ; or hypersensitivity to any of the ingredients. 
A·H·ROBI NS AH. Robins Company Richmond. Virginia 23220 

